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The overall goal of this thesis is to develop novel molecular imaging strategies for the targeted 
imaging of inflammation-related biomarkers of disease. In particular, these strategies focus on the 
careful development and assessment of molecular imaging agents targeting relevant disease 
markers related to cancer (fibroblast activation protein), neurodegenerative disease (nicotinic 
acetylcholine receptors and soluble epoxide hydrolase), and fibrosis (death receptor 5). We aim to 
show the feasibility and importance of these efforts in the following 6 chapters. In chapter 1, we 
provide an introduction to molecular imaging, discuss inflammation-related biomarkers of diseases, 
and outline the scope of the dissertation. In chapter 2, we focus on the development of small 
molecule imaging agents targeting fibroblast activation protein and the assessment of these agents 
in in vitro and in vivo cancer models. In chapters 3-5, we focus on the kinetic modeling of three 
separate molecular imaging agents, [18F]FNDP, [18F]XTRA, and [18F]ASEM targeting soluble epoxide 
hydrolase (sEH) and nicotinic acetylcholine receptors (nAChRs) in the brain. Chapters 3 and 4 focus 
on first in human studies of [18F]FNDP and [18F]XTRA, respectively, whereas in chapter 5 we focus 
on a study of [18F]ASEM distribution with healthy aging. Finally, in chapter 6, we focus on the 
development of new peptide-based imaging agents directed at the engagement of death receptor 5 
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Chapter 1: Introduction 
Introduction to Molecular Imaging 
Molecular imaging can be defined as the visualization and characterization of biological processes at 
the molecular and cellular level1. A distinct advantage of molecular imaging is its non-invasive 
nature, allowing it to characterize disease processes in vivo without relying on surgical procedures or 
biopsies2. This has led to the application of molecular imaging beyond just disease detection, but 
also in the development of precision medicine therapies and drug development3. Molecular imaging 
is impacting medicine directly by helping detect disease in early stages, acting as a guide for 
determining patient-specific therapies, and measuring the effects of targeted therapies at a 
molecular level2. Molecular imaging research is characterized by the combination of various 
technologies, such as imaging modalities and molecular imaging agents, in order to generate 
information on imaging targets. Due to the broad nature of this field, the majority of molecular 
imaging research is highly multidisciplinary, with teams composed of chemists, biologists, imaging 
scientists, and clinical experts working together to achieve their research goals. Due to the broad 
nature of this field, molecular imaging strategies have been employed to answer questions in various 
realms of research, including neuroscience4, inflammatory diseases5, cancer6, cardiology7, and 
theranostics8.  
 
The majority of molecular imaging modalities can be categorized into two groups: functional imaging 
techniques and anatomical imaging techniques (Figure 1-1). Functional imaging techniques are 
characterized by the ability to detect changes in biochemical processes at the molecular and cellular 
level and usually rely on an imaging agent or “probe” to provide information at the site of interest. 
Popular in both clinical and preclinical settings, single photon emission computed tomography 
(SPECT) and positron emission tomography (PET) employ radionucleotide-based imaging agents to 
image and detect changes in activity in tissues of interest. Optical and fluorescent imaging 




Figure 1-1. A summary of imaging modalities used for molecular imaging. 




 preclinical setting9. These techniques are characterized by high sensitivity but lack spatial 
resolution. In contrast, anatomical imaging techniques provide high structural resolution and provide 
detailed information on the structure that is being imaged. These techniques include computed 
tomography (CT), ultrasound (US), and magnetic resonance imaging (MRI) and are commonly 
employed in both clinical and preclinical applications. To advantage of the strengths of the various 
imaging techniques, anatomical and functional imaging techniques are commonly combined, 
resulting in molecular imaging strategies that can provide powerful information on targets of interest 
in vivo10. 
 
A central part of molecular imaging research is the identification of disease-specific targets and 
finding ligands that interact with those targets. This process has been greatly assisted with the rise 
of “omics” research, with more and more disease-associated targets being identified and studied6. 
Once a target has been identified, the careful development and characterization of molecular 
imaging agents is the next crucial step. Molecular imaging agents are usually comprised of two 
parts, a signal and a targeting moiety. The signal component is application-dependent, and its main 
function is to report back a signal to the imaging modality so it can generate an image. The targeting 
moiety is what directs the imaging agent to the target of interest and can take on a variety of forms, 
including small-molecules, peptides, antibodies, antibody fragments, aptamers, and nanoparticles11. 
These components are usually connected with a linker, which bounds the signal to the targeting 
moiety and helps tune the pharmacokinetic properties of the agent12. The combination of signal, 
targeting moiety, and linker should be optimized for each molecular imaging application to ensure 
favorable pharmacokinetics, binding specificity, and stability of these agents. 
 
The development and validation of molecular imaging agents is very similar to the drug-development 
pipeline13. Once a target of interest has been identified, the imaging agent is designed and a 
synthesis approach is developed. Next, the imaging agent goes through lead compound 
optimization, where the agent is assessed for its binding ability and specificity for the target of 
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interest. This process is important and often revisited many times to ensure that the agent has 
favorable chemical properties before moving towards further testing. Usually done in conjunction 
with this is the preclinical assessment of the agent in cellular and small animal models. This step is 
crucial to understand how the agent is behaving in vivo and evaluating the pharmacokinetic and 
biodistribution properties of the agent of interest. If the agent is showing favorable properties, the 
agent will move forward toward larger animal testing, commonly small primates like baboons, before 
moving towards human clinical studies. Like the drug development pipeline, many molecular imaging 
agents don’t make it to the end of the pipeline and to use in the clinical setting, so there is increasing 
interest in optimizing this process in order to increase the success of new molecular imaging agents 
in development14. 
Inflammation-Related Biomarkers of Disease 
Inflammation is the immune system’s response to harmful stimuli such as bacteria, viruses, toxins, 
and injury15. The goal of the inflammatory response is to eliminate pathogens and promote tissue 
repair and recovery16. Inflammation is initiated by tissue resident cells that detect pathogen-
associated molecular patterns (PAMPs) and/or damage-associated molecular patterns (DAMPs), 
which then recruit additional immune cells of the innate and adaptive immune system through 
release of cytokines and chemokines17. This leads to a local inflammatory environment the enables 
the transport of cells from the blood stream to the site of inflammation by changes in vascular 
permeability, blood flow, and endothelial adhesion18. A normal inflammatory response is 
characterized by the temporary upregulation of inflammatory activity while a DAMP and/or PAMP is 
present followed by resolution and tissue repair19. In contrast, chronic inflammatory responses occur 
when acute inflammatory processes fail to eliminate tissue injury and are characterized by a 
persistent inflammatory state, the infiltration of macrophages and lymphocytes, and dysregulated 
tissue remodeling20. Chronic inflammation is implicated in a variety of diseases, including cancer, 




Fibroblast Activation Protein 
Fibroblast activation protein (FAP), a serine protease, is a member of the dipeptidyl peptidase (DPP) 
family of proteins, which are known for their unique ability to cleave prolyl bonds two residues from 
the N terminus21. While FAP expression in normal tissues is minimal, it is highly upregulated in the 
chronic inflammatory environment of cancer, with FAP being expressed in over 90% of epithelial 
tumors22. FAP is expressed by both cancer epithelial cells and the surrounding stromal cells in the 
tumor microenvironment23. That expression supports tumorigenesis by contributing to an active 
cancer stroma and participating in the enzymatic remodeling of the ECM essential for cancer cell 
invasion and metastasis24. 
Nicotinic Acetylcholine Receptors 
Nicotinic acetylcholine receptors (nAChRs) are members of the Cys-loop superfamily of pentameric 
ligand-gated ion channels25. The most commonly expressed nAChR subtypes in mammalian central 
nervous system (CNS) are the heteromeric α4β2 and homomeric α7 subtypes. The discovery that 
α4β2 and α7 nAChRs were abundantly expressed in the CNS and that they play an important role in 
neurotransmission and neuronal integration led to increased interest in understanding the role these 
receptors play in neurodegenerative disease. Neurodegenerative diseases are characterized by 
neuroinflammation and are characterized by an altered distribution of the α4β2 and α7 nAChRs. In 
general, there is an observed loss of the α4β2 nAChR in the presence of neurodegenerative 
disease26. In contrast, an increase in the density of the α7 nAChR is observed in neurodegenerative 
disease, likely due to the suspected role this receptor plays in the cholinergic anti-inflammatory 
pathway27. 
Soluble Epoxide Hydrolase 
Soluble epoxide hydrolase (sEH) is an enzyme that metabolizes anti-inflammatory epoxy fatty acids 
to relatively inert 1,2-diol forms. In this manner, the availability and activity of sEH may critically 
control the bioavailability of epoxyeicosatrienoic and epoxydocosapentaenoic acids that have 
vasoactive and anti-inflammatory roles. sEH is expressed widely throughout the body and a high 
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availability or activity of this enzyme may promote inflammation in local tissues28. This promotion of 
an inflammatory microenvironment may exacerbate pathological changes in several clinical 
conditions, such as vascular cognitive impairment (VCI) where greater sEH expression was 
observed in subjects with VCI versus age matched controls29. 
Death Receptor 5 
Death receptor 5 (DR5) triggers apoptosis upon binding of tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL). This apoptosis can be triggered either through the extrinsic or intrinsic 
apoptotic pathways. Recently, there has been an interest in the role of death receptor 5 in fibrosis. In 
a study of scleroderma, it was observed that in skin biopsies of patients with systemic sclerosis there 
was an upregulation of mRNA DR5, which was mainly colocalized with smooth muscle actin positive 
(aSMA+) myofibroblasts30. In wound healing, myofibroblasts help initiate the scarring process31, but 
in the case of chronic inflammation, they are overactive and contribute to fibrosis32. Similar results 
were observed in liver fibrosis, where activated hepatic stellate cells (aHSCs), the major cell type 
responsible for liver fibrosis, in liver sections of patients with liver cirrhosis upregulated death 
receptor 5 compared to healthy liver tissues33. Taken together, this has led to increased interested in 
the role of death receptor 5 in fibrosis and how its expression plays a role in the control of apoptosis 
in fibrotic diseases. 
Scope of Dissertation 
The overall goal of this thesis is to develop novel molecular imaging strategies for the targeted 
imaging of inflammation-related biomarkers of disease. In particular, these strategies focus on the 
careful development and assessment of molecular imaging agents targeting relevant disease 
markers related to cancer (fibroblast activation protein), neurodegenerative disease (nicotinic 
acetylcholine receptors and soluble epoxide hydrolase), and fibrosis (death receptor 5). We aim to 
show the feasibility and importance of these efforts in the following 5 chapters. In chapter 2, we 
focus on the development of small molecule imaging agents targeting fibroblast activation protein 
and the assessment of these agents in in vitro and in vivo cancer models. In chapters 3-5, we focus 
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on the kinetic modeling of three separate molecular imaging agents, [18F]FNDP, [18F]XTRA, and 
[18F]ASEM targeting soluble epoxide hydrolase (sEH) and nicotinic acetylcholine receptors 
(nAChRs) in the brain. Chapters 3 and 4 focus on first in human studies of [18F]FNDP and 
[18F]XTRA, respectively, whereas in chapter 5 we focus on a study of [18F]ASEM distribution with 
healthy aging. Finally, in chapter 6, we focus on the development of new peptide-based imaging 
agents directed at the engagement of death receptor 5 and initial in vitro assessment of these 




Chapter 2: Development and assessment of inhibitor-
based agents for targeted molecular imaging of fibroblast 
activation protein alpha (FAP)  
Summary: 
The focus of this chapter is on the development of small molecule imaging agents targeting FAP and 
the assessment of these agents in in vitro and in vivo cancer models. These agents, inspired by 
FAP-specific inhibitors with a (4-quinolinoyl)-glycyl-2-cyanopyrrolidine scaffold, will be assessed for 
their ability to inhibit FAP binding after chemical modification. To gain a deeper knowledge of FAP 
expression in cancer, we will examine FAP expression in cancer cell lines and human primary 
tumors using database-driven analyzes. Then we will assess the binding ability and specificity of 
these agents in cell-based cancer models, specifically looking at selectively of these agents for FAP 
over DPP-IV, an enzyme of the sample family in which it shares significant sequence and structural 
homogeneity. After characterization in vitro, we will determine the biodistribution and specificity of 




Imaging of fibroblast activation protein in cancer xenografts using novel (4-
quinolinoyl)-glycyl-2-cyanopyrrolidine-based small molecules 
 
This work has been published and is reprinted here with permission by The Journal of Medicinal 
Chemistry. 
 
Slania SL, Das D, Lisok A, Du Y, Jiang Z, Mease RC, Rowe SP, Nimmagadda S, Yang X, Pomper 
MG. Imaging of fibroblast activation protein in cancer xenografts using novel (4-quinolinoyl)-glycyl-2-




Fibroblast activation protein (FAP) has become a favored target for imaging and therapy of 
malignancy. We have synthesized and characterized two new (4-quinolinoyl)-glycyl-2-
cyanopyrrolidine-based small molecules for imaging of FAP, QCP01 and [111In]QCP02, using optical 
and single-photon computed tomography/CT, respectively. Binding of imaging agents to FAP was 
assessed in six human cancer cell lines of different cancer types: glioblastoma (U87), melanoma 
(SKMEL24), prostate (PC3), NSCLC (NCIH2228), colorectal carcinoma (HCT116), and lung 
squamous cell carcinoma (NCIH226). Mouse xenograft models were developed with FAP-positive 
U87 and FAP-negative PC3 cells to test pharmacokinetics and binding specificity in vivo. QCP01 
and [111In]QCP02 demonstrated nanomolar inhibition of FAP at Ki values of 1.26 and 16.20 nM, 
respectively. Both were selective for FAP over DPP-IV, a related serine protease. Both enabled 
imaging of FAP-expressing tumors specifically in vivo. [111In]QCP02 showed high uptake at 18.2 





Fibroblast activation protein (FAP) is highly upregulated at sites of active tissue remodeling, 
including wound healing, fibrosis, and cancer23,34–36. It is a member of the dipeptidyl peptidase (DPP) 
family of serine proteases known for their unique ability to cleave prolyl bonds two residues from the 
N-terminus21. FAP has the ability to cleave after prolyl bonds within peptides (not just at the N-
terminus), which enables it to act as a collagenase and cleave type I collagen37–40. The collagenase 
activity of FAP is a major driver in the remodeling of the extracellular matrix (ECM) in a variety of 
diseases, including cancer38,40,41. While FAP expression in normal tissues is minimal, it is highly 
upregulated in cancer, with presence in over 90% of epithelial tumors22. 
 
In cancer, FAP has emerged as a distinct marker of cancer-associated fibroblasts (CAFs) and a key 
regulator and driver of the tumor microenvironment (TME). CAFs are one of the largest components 
of the TME and promote tumor growth and cell invasion by secreting pro-inflammatory factors and 
growth factors as well as remodeling the ECM42,43. In addition to cells within the TME, FAP 
expression can be present within malignant epithelial cells44. FAP promotes tumor growth through 
ECM remodeling, which leads to the formation of an active cancer stroma, essential for cancer cell 
invasion and metastasis24. This has been observed clinically, where FAP expression was increased 
at the invasive front of tumor samples of colorectal cancer, further supporting its role in invasion and 
metastasis45. FAP also contributes to the formation of an immunosuppressive TME by enabling 
tumor-promoting inflammation46. Due to the important roles FAP plays in the TME, there is 
increasing interest in utilizing it as a target for imaging and therapy. 
 
Clinical studies show that FAP expression has prognostic value in a variety of cancers. In pancreatic 
cancer, FAP expression is related directly to poor clinical outcome. Patients with pancreatic cancer 
and high FAP expression have lower chances of overall and disease-free survival47. In non-small-
cell lung cancer (NSCLC), a larger percentage of cells staining positively for FAP and a higher FAP-
staining grade were both significant predictors of poor overall survival48. Henry et al. observed 
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similar results in colon cancer, where patients with high levels of tumor stromal FAP expression were 
more likely to progress and develop metastases49. These results, generated from biopsy specimens, 
have motivated the search for ways to interrogate FAP concentration in vivo, preferably non-
invasively so that repeat measurements would be possible. 
 
Antibody-based imaging agents targeting FAP were first tested clinically over 25 years ago50, with 
immuno-positron emission tomography (PET) of FAP having more recently been used in preclinical 
models, such as to delineate rheumatoid arthritis51. However, the small-molecule FAP-targeting 
agents have captured the most attention recently. Such compounds, if suitably functionalized, 
promise to have superior and modifiable pharmacokinetics, enabling imaging soon after injection, 
among other advantages of using drug-like molecules for imaging. 
 
A variety of small-molecule FAP inhibitors have been functionalized for imaging. MIP-1232, based 
on a boronic acid FAP inhibitor, demonstrated its ability to bind FAP-positive SK-MEL-187 
(melanoma) xenografts52. However, boronic acid FAP inhibitors often have affinity for multiple prolyl 
peptidases related to FAP, limiting the specificity of these agents53,54. Lindner et al. recently 
developed theranostic agents55 based on the specificity of the (4-quinolinoyl)-glycyl-2-
cyanopyrrolidine nucleus of general structure 2 targeting FAP (Figure 2-), originally reported by 
Jansen et al.56,57 While the radioiodinated inhibitor FAPI-01 (Figure 2-) suffered from rapid 
deiodination, radiometal complexes of FAPI-02 or FAPI-04 (68Ga or 177Lu, Figure 2-) exhibited high 
and rapid uptake in FAP-expressing cells and mouse xenograft models58. Early clinical studies of 
those agents in pancreatic, head and neck, colon, lung, and breast cancers indicate that both 
[68Ga]FAPI-02 and [68Ga]FAPI-04 can be used to detect FAP expression in primary tumors as well 
as metastatic lesions and indicate the potential of FAP-targeted imaging to visualize the components 
of the TME59. Roy et al. have also recently leveraged the 2-cyanopyrolidine moiety for FAP binding, 
but utilized a pyridine rather than a quinoline to link to a variety of imaging and therapeutic 




Despite the use of FAP-targeted small-molecule PET agents in clinical studies, a comprehensive 
preclinical evaluation has not been carried out to ascertain an optimal compound for clinical use. 
Here, we build toward a more complete understanding of these agents with the preclinical 
development of two novel FAP-targeted imaging agents based on the (4-quinolinoyl)-glycyl-2-
cyanopyrrolidine scaffold, QCP01 and [111In]QCP02. These agents are equipped for near-infrared 
fluorescence (NIRF) and single-photon emission computed tomography (SPECT) imaging, 
respectively. QCP01 and QCP02 share the same (4-quinolinoyl)-glycyl-2-cyanopyrrolidine scaffold 
as FAPI-02 but differ in the linking group using a flexible linear linker instead of one containing a 
semi-rigid piperazine moiety, potentially allowing for better penetration into the binding site. Also, the 
chelating group, 2-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra acetate (DOTA-GA) in QCP02, 
contains an additional carboxylate group compared to the chelator in FAPI-02 and FAPI-04, 
increasing affinity for radiometals, including 111In61,62. We chose 111In as the imaging radionuclide 
because of the high affinity to DOTA-GA, its ready detectability with SPECT by virtue of two emitted 
photons (171 and 245 keV), and its long physical half-life (2.8 days), which could accommodate 
lengthy imaging times after administration if needed63. We evaluated the affinity and specificity of 
these agents in vitro and studied their abilities to image cancer xenografts in mouse models. 
Additionally, to examine further the role of FAP in cancer, we analyzed the FAP expression profiles 
in the Cancer Cell Line Encyclopedia (CCLE) and The Cancer Genome Atlas (TCGA) data sets. 
Results and Discussion 
Chemical Synthesis 
The FAP binding reactive moiety was synthesized by coupling 6-hydroxyquinoline-4-carboxylic acid 
(3) with glycine methyl ester hydrochloride to give 4. Alkylation of 4 with tert-butyl-1-(3-
bromopropyl)carbamate produced 5, which underwent basic hydrolysis to give acid 6 (Figure 2-2). 
Compound 6 was coupled with (S)-2-pyrrolidine carbonitrile hydrochloride to produce the common 
intermediate 7. QCP01 was prepared by acid deprotection of 7 to produce intermediate 8, which was 
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conjugated with IRDye 800CW-NHS (LI-COR Biosciences, Lincoln, NE) under basic conditions. 
Similarly, QCP02 was prepared by conjugation with DOTA-GA(t-Bu)4-N-hydroxysuccinimide 
(NHS)64, followed by acid hydrolysis of the tert-butyl ester groups. Complexation of non-radioactive 
113/115In (III) and radioactive 111In (III) with QCP02 was carried out in 0.2 M sodium acetate buffer (pH 
5.5–6.0) at 70 °C, followed by purification with reverse-phase semi-preparative high-performance 
liquid chromatography (HPLC). The isolated yields of [113/115In]QCP02 and [111In]QCP02 were 79 and 
69–74%, respectively (n = 4). The radiochemical purity of [111In]QCP02 was >95%, as measured by 
radio-HPLC (Supplemental Figure 2-1). Both QCP02 and QCP01 were sterile-filtered and formulated 
in saline solution prior to use. 
FAP Inhibitory Capacity 
To determine potency toward FAP, we measured the inhibitory capacity of QCP01 and 
[113/115In]QCP02 against a fluorogenic FAP substrate (Ala-Pro-AMC) of human recombinant FAP 
(Supplemental Figure 2-2). QCP01 demonstrated low nanomolar inhibition of FAP with a Ki of 1.26 
nM (95% confidence interval: 0.95–1.67 nM). [113/115In]QCP02 also showed strong inhibition, with a 
Ki value of 16.20 nM (95% confidence interval: 10.34–26.37 nM). These results demonstrated the 
FAP binding potential of the synthesized compounds and showed that functionalization of the 
inhibitor scaffold did not substantially affect its inhibition of FAP in vitro. 
FAP Expression in Human CCLE Database-Derived and Primary Tumor-Derived TCGA 
Data Sets 
Due to the prominent role FAP plays in cancer and the lack of understanding of its expression 
across the cancer spectrum, we wanted to gain a detailed picture of FAP expression in cancer cell 
lines as well as in primary tumor samples. To do so, we obtained gene expression data on FAP from 
1047 cancer cell lines from the CCLE database to examine the heterogeneity of FAP expression 
across cancer cell types. Cancer cell lines that showed high FAP expression include fibroblast-like, 
glioma, melanoma, osteosarcoma, and upper aerodigestive cancers (Figure 2-3A). Low FAP 
expression was seen in a variety of leukemia and lymphoma subtypes as well as in prostate cancer. 
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Using these results, we chose six cancer cell lines of different cancer types for in vitro studies from 
the high- and low-expression subtypes. 
 
Further analysis of the TCGA data set allowed us to examine FAP expression in primary tumor 
samples across 32 different cancers. Similar to the CCLE results, we observed that FAP expression 
in primary tumor samples varied across cancer types (Figure 2-3B). High FAP expression was seen 
in pancreatic ductal adenocarcinoma, a cancer where stroma is known to play a prominent role65. 
Other cancers including breast, mesothelioma, and head and neck also showed high FAP 
expression. In contrast, low FAP expression was seen in thymoma and acute myeloid leukemia. 
Additionally, when comparing FAP expression between primary tumor and normal solid tissue 
samples, we saw that in a majority of cancer types, FAP expression was higher in primary tumors 
compared to the corresponding normal tissue (Figure 2-3C). Further analysis of FAP expression in 
primary melanoma and metastases showed a trend in increase in FAP expression in metastases but 
had no statistical significance (Supplemental Figure 2-4). 
In Vitro Fluorescence 
All six selected cell lines were tested for FAP expression by flow cytometry (Supplemental Figure 2-
3) and observed to have variable FAP expression levels (Figure 2-4). For in vitro binding studies, 
binding of QCP01 was observed in all three FAP-positive cell lines (Figure 2-4A). QCP01 binding 
was observed at concentrations as low as 1.56 nM and exhibited concentration-dependent binding 
that was saturated at 50 nM. In contrast, no specific binding of QCP01 was observed in FAP-
negative cell lines at any of the concentrations tested. This was further illustrated in the binding 
curves, which showed that the FAP-negative cell lines exhibited minimal binding of QCP01 (Figure 
2-4A). 
 
Cellular binding of [111In]QCP02 was also assessed in vitro. After incubation with [111In]QCP02 and 
subsequent washing, FAP-positive U87 cells demonstrated over 30% binding of the incubated dose 
of [111In]QCP02 (0.037 MBq) (Figure 2-4B). In contrast, FAP-negative PC3 cells showed 0.01% 
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binding of the incubated dose. This difference in binding of [111In]QCP02 was significant between the 
FAP-positive and FAP-negative cell lines, with a P-value of <0.001. 
 
To examine the specificity of our compounds further, inhibition studies were performed in the FAP-
positive cell lines (U87, NCIH228, and SKMEL24) using QCP01. Cells were pretreated with either 
Val-boroPro (IC50; FAP: 0.066 ± 0.011 μM, DPP-IV: 0.022 ± 0.001 μM)66 or sitagliptin, (IC50; FAP: 
>100 μM, DPP-IV: 0.04 ± 0.001 μM)66, followed by incubation with QCP01. When pretreated with 
Val-boroPro, FAP-positive cell lines demonstrated dose-dependent inhibition of the fluorescence 
signal, indicating decreased binding of QCP01 with increasing concentration of Val-boroPro (Figure 
2-4C). In contrast, QCP01 binding by FAP-positive cell lines was not inhibited by pretreatment with 
sitagliptin. These results show that QCP01 binds to FAP and not DPP-IV when binding to target cells 
since inhibition of DPP-IV alone did not affect binding of QCP01. Taken together, the results 
establish the specificity of QCP01 to bind FAP in vitro. 
NIRF Imaging of QCP01 in a Murine Xenograft Model 
To evaluate the ability of QCP01 to bind FAP in vivo and to gain insight into its biodistribution, we 
performed NIRF imaging in tumor-bearing mice. NIRF imaging results illustrated the 
pharmacokinetic behavior of QCP01 in vivo. Emission from intact, living, and unshaven tumor-
bearing mice demonstrated uptake of QCP01 in U87 xenografts at 30 min after injection 
(Supplemental Figure 2-5). This uptake persisted up to 5 h after injection, with washout after 24 h. 
PC3 tumors showed mild uptake of QCP01 at 30 min after injection until 5 h, with washout at 24 h. 
QCP01 uptake in normal tissues was observed to a mild degree (moderate in the kidney) at 30 min 
after injection and washed out slowly over time. At 5 h after injection, post-mortem studies were 
performed to enable exposure of organs for NIRF imaging (Figure 2-5). Although difficult to quantify 
as the image is planar, one can observe increased binding of QCP01 in the FAP-positive U87 
xenograft compared to that in the FAP-negative PC3 xenograft. This difference was further 
pronounced in the ex vivo organ tissue, with the excised U87 tumor consistently showing higher 
QCP01 uptake than the PC3 tumor at 5, 24, and 48 h after injection. 
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SPECT-CT Imaging and Biodistribution of [111In]QCP02 in a Murine Xenograft Model 
SPECT-CT imaging showed high and specific uptake of [111In]QCP02 in U87 xenografts (Figure 2-6) 
as early as 1 h post injection and was retained for up to 10 h. In contrast, low uptake of [111In]QCP02 
in the PC3 xenografts was observed at all imaging time points, further demonstrating the in vivo 
specificity of [111In]QCP02 for FAP. Ex vivo biodistribution of [111In]QCP02 correlated with the 
observed SPECT-CT imaging results (Figure 2-6, Supplemental Table 2-1). [111In]QCP02 uptake in 
the U87 xenograft was 3–4-fold higher than that in the PC3 xenograft (16.09 ± 4.17 vs 4.12 ± 0.36% 
ID/g at 1 h, P < 0.0012) at all time points. At as early as 5 min, the tumor uptake in U87 was over 
10% ID/g, which peaked at 30 min post injection (18.16 ± 11.67% ID/g) and remained between 16 
and 8% ID/g for up to 6 h. In contrast, the PC3 tumor uptake was less than 5% ID/g at all time 
points, which was similar to the radioactivity in blood. Washout of the radiotracer in U87 tumors was 
observed by 28 h post injection. Additionally, co-injection of non-radioactive QCP02 with 
[111In]QCP02 significantly reduced radiotracer uptake in U87 xenografts (7.63 ± 1.39 vs 0.55 ± 
0.23% ID/g; P < 0.0001), establishing the specific binding of the radiotracer to FAP. Altogether, the 
results establish the ability of QCP01 and [111In]QCP02 to bind FAP in vivo and clear rapidly from 
non-target tissues. 
 
FAP provides a distinct marker of activated fibroblasts and is a key regulator and driver of the TME. 
Activated fibroblasts, also known as CAFs, are one of the largest components of the TME in many 
cancers. They promote tumorigenesis by secreting pro-inflammatory cytokines and growth factors, 
including the vascular endothelial growth factor, as well as by remodeling the ECM to enhance tumor 
cell invasion42,43. Additionally, FAP expression is not limited to fibroblasts but can also be seen on 
tumor epithelial cells44, which can then support and accelerate tumorigenesis. This phenomenon has 
been demonstrated clinically, where FAP expression levels have been linked to poor outcomes47–49. 
Mounting evidence for the role of FAP in cancer explains the rapid adoption of small-molecule 




The rapidity with which preclinical studies progressed to the clinic may suggest that limited medicinal 
chemistry was undertaken to optimize the agents that are being utilized in patients. Indeed, a 
number of new agents have been developed and studied preclinically, which may have superior 
characteristics to the most commonly used clinical compound60,67. First, we provided a 
comprehensive summary of FAP-expressing cells and tissues from the CCLE and TCGA and chose 
six lines to test our compounds. 
 
Here, we report the syntheses, FAP binding affinities and specificities, and in vivo uptake of two new 
imaging agents targeting FAP in an experimental model. Novel aspects of this work include our co-
development of an optical agent, QCP01, to examine the dynamics of FAP binding by this 
compound both in vitro and in vivo. Despite introduction of the bulky optical moiety to the (4-
quinolinoyl)-glycyl-2-cyanopyrrolidine scaffold, QCP01 retained FAP inhibitory capacity. The SPECT-
CT imaging agent, [111In]QCP02, enabled us to investigate FAP expression and target selectivity in 
mice quantitatively. The use of a common FAP-binding intermediate having a reactive amine moiety 
permits the ready conjugation of any number of amine reactive optical dyes, metal chelating groups, 
or radiolabeled prosthetic groups for SPECT/PET imaging and theranostic applications. 
 
Using QCP01 and [111In]QCP02, we demonstrated the ability of our agents to target FAP on the 
surface of known FAP-positive cancer cells in vitro with minimal non-specific binding in FAP-
negative cancer cells. Even within FAP-positive cell lines, we saw distinct differences in binding of 
FAP (Figure 2-4A), further illustrating the heterogeneity of FAP expression within highly expressing 
cells and the sensitivity of our compounds for detecting these differences. To explore further the 
dynamics of FAP in cancer, we employed a tumor xenograft model with two cancer cell lines, FAP-
positive U87 and FAP-negative PC3, in NOD/SCID mice. When we expanded these studies to in 
vivo imaging and biodistribution, we saw that the agents behaved similarly with favorable 




Since FAP shares over 50 and 70% similarity in the sequence and catalytic region, respectively, with 
DPP-IV, most inhibitors of FAP also bind to DPP-IV40. Due to the ubiquitous expression of DPP-IV in 
normal human tissues40, it was important to establish the specificity of imaging compounds of this 
class for FAP over DPP-IV. The specific binding of QCP01 and [111In]QCP02 for FAP was verified in 
cellular studies of various cell lines with differing FAP expression. In vitro blocking studies also 
showed the specificity of QCP01 for FAP over DPP-IV. In blocking studies, there was no change in 
binding of QCP01 when only DPP-IV binding was inhibited. In contrast, binding of QCP01 was 
blocked when DPP-IV and FAP were both inhibited. This was further supported in the biodistribution 
study for [111In]QCP02. This study showed that when a blocking dose was administered, no binding 
was observed in the FAP-positive xenograft, ruling out a substantial role for flow-mediated 
phenomena accounting for the observed activity within FAP-expressing tumors. 
 
Although both QCP01 and [113/115In]QCP02 have low-nanomolar inhibition, they differ by about 1 
order of magnitude, with the former demonstrating greater inhibitory capacity. There were distinct 
differences between QCP01 and [111In]QCP02 in vivo. While both compounds demonstrated uptake 
in the FAP-positive U87 xenograft at early time points and clearance through the gastrointestinal 
tract, QCP01 showed more non-specific uptake than [111In]QCP02. These differences in uptake 
could be attributed to factors besides binding affinity, such as molecular weight and lipophilicity. 
 
In comparison to other FAP-targeted imaging agents, [111In]QCP02 demonstrated both higher tumor 
and normal organ uptake relative to FAPI-02 and FAPI-04, which were evaluated in stably 
transfected FAP cell lines55. [111In]QCP02 also appears to have significantly higher uptake in the 
tumor and lower uptake in the kidney than another recently reported small-molecule agent, although 
again in different cell line xenografts60. The optimum imaging time for [111In]QCP02 to make the best 
use of its high tumor uptake would appear to be ∼30 min post-injection in our mouse xenograft 




Because of an improved understanding of the TME in tumor progression and resistance to therapy68, 
there has been a paradigm shift in cancer treatment to focus on targeting the tumor stroma and 
other aspects of the TME in addition to the cancer cells themselves43,69. FAP can promote 
generation of regulatory T-cells and tumor-associated macrophages, contributing to the 
immunosuppressive tumor environment70. Active monitoring of targeted treatments with FAP 
imaging agents may promote optimal cancer management strategies. 
Conclusions 
We prepared two high-affinity FAP-targeted agents, QCP01 and [111In]QCP02, and demonstrated 
their specificity for FAP in vitro and in vivo. We initially tested them in cellulo based on the variable 
expression of FAP noted in a variety of cell lines and tissues according to the CCLE and TCGA. In 
mouse xenograft models with variable FAP expressions, both agents exhibited significant retention 
in FAP-positive tumors. The favorable pharmacokinetics and biodistribution observed with these 
agents provided FAP-specific images by 30 min after injection and also allow for imaging at later 




Reagents and solvents were purchased from commercial sources and were of analytical or HPLC 
grade, which were used as received. 6-Hydroxyquinoline-4-carboxylic acid was purchased from 
Sigma-Aldrich (St. Louis, MO). Methyl glycinate hydrochloride, 2-(1H-benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU), 1-hydroxylbenzotriazole monohydrate (HOBt), 
and diisopropylethylamine were purchased from Chem Impex International Inc. (Wood Dale, IL). 3-
(Boc-amino) propyl bromide and (S)-pyrrolidine-2-carbonitrile hydrochloride were purchased from 
Combi-Blocks (San Diego, CA). 2-[1,4,7,10-Tetraazacyclododecane-4,7,10-tris(t-butyl acetate)]-
pentanedioic acid-1-tert-butyl ester [DOTAGA-tetra(tert-Bu ester); DOTA-GA] was purchased from 
Macrocyclics (Dallas, TX). IRDye 800CW NHS ester was purchased from LI-COR Biosciences 
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(Lincoln, NE). Reaction progress was monitored by analytical thin-layer chromatography and was 
performed on Analtech Uniplate 0.25 mm silica gel 60 F254 plates. Visualization was accomplished 
with ultraviolet (UV) light. Purification of reaction products was carried out by reverse-phase 
chromatography using a C18 cartridge (Silicycle, Canada) on a Biotage IsoleraOne flash purification 
system. HPLC purification was performed using a Phenomenex C18 Luna 10 × 250 mm2 column on 
an Agilent Technologies 1260 Infinity semi-preparative HPLC System (Wilmington, DE). HPLC 
purification of the 111In-labeled compound was performed on an Agilent PrepStar system (Santa 
Clara, CA), equipped with an Agilent ProStar 325 UV–vis variable wavelength detector and a 
Bioscan Flow-count in-line radioactivity detector (Washington, DC), with all controlled by OpenLAB 
software. Proton nuclear magnetic resonance spectra (1H NMR) were recorded on a Bruker 
UltraShield 400 MHz instrument and are reported in ppm using the solvent as an internal standard 
(CDCl3 at 7.26 ppm and CD3OD at 3.31 ppm). Data are reported as app = apparent, br = broad, s = 
singlet, d = doublet, t = triplet, q = quartet, m = multiplet, and comp = complex, and coupling 
constant(s) are reported in Hz. Proton-decoupled carbon nuclear magnetic resonance spectra (13C 
NMR) were recorded on a Bruker UltraShield 400 MHz instrument and are reported in ppm using the 
solvent as an internal standard (CDCl3 at 77.0 ppm and CD3OD at 49.00 ppm). Low-resolution 
electrospray ionization-mass spectrometry (ESI-MS) data were obtained using an Agilent 
Technologies 1260 series LCMS Single Quad System connected to a variable wavelength detector. 
High-resolution mass spectra were recorded at the University of Notre Dame Mass Spectrometry 
and Proteomics Facility (Notre Dame, IN) using ESI by direct infusion on a Bruker microTOF-II. 
Methyl (6-Hydroxyquinoline-4-carbonyl)glycinate (4) 
6-Hydroxyquinoline-4-carboxylic acid (3) (210 mg, 1.1 mmol), methyl glycinate HCl salt (143 mg, 1.1 
mmol), HBTU (420 mg, 1.1 mmol), and HOBt (170 mg, 1.1 mmol) were dissolved in 12 mL of dry 
dimethylformamide (DMF). To the solution, N,N-diisopropylethylamine (DIPEA) (0.77 mL, 4.4 mmol) 
was added. The reaction mixture was stirred at room temperature (RT) for 6 h. After the solvent was 
removed under vacuum, the mixture was loaded onto a 25 g C18 cartridge and the product was 
purified with a MeCN/water/trifluoroacetic acid (TFA) gradient (0/100/0.1 to 90/10/0.1). After 
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lyophilization, product 4 was obtained as a yellow powder in a 76% yield (290 mg). 1H NMR (400 
MHz, CD3OD): δ 8.69 (s, 1H), 7.94 (d, J = 7.92 Hz, 1H), 7.57–7.51 (m, 3H), 7.42–7.37 (m, 1H), 4.21 
(s, 2H), 3.81 (s, 3H). 13C NMR (100 MHz, CD3OD): δ 172.4, 160.9, 145.1, 143.7, 129.7, 129.4, 
128.3, 121.8, 119.6, 112.4, 109.1, 56.8, 44.8. ESI-MS m/z: calcd for C13H13N2O4 [M + H]+, 261.3; 
found, 261.1. 
Methyl (6-(3-((tert-Butoxycarbonyl)amino)propoxy)quinoline-4-carbonyl)glycinate (5) 
Methyl (6-hydroxyquinoline-4-carbonyl)glycinate (3) (360 mg, 1.0 mmol) and 3-(Boc-amino) propyl 
bromide (4) (500 mg, 2.1 mmol) were dissolved in 20 mL of DMF. Cs2CO3 (1 g, 3.0 mmol) was 
added to the solution, and the reaction mixture was stirred at RT overnight. After filtration, the 
solvent was removed under vacuum and the remaining mixture was loaded onto a 25 g C18 
cartridge. The product was purified with a MeCN/water/TFA gradient (0/100/0.1 to 90/10/0.1). After 
lyophilization, 270 mg of product 5 was obtained in a 54% yield. 1H NMR (400 MHz, CDCl3): δ 8.68–
8.37 (m, 2H), 8.02 (d, J = 9.1 Hz, 1H), 7.80 (s, 1H), 7.72–7.64 (m, 1H), 7.40 (d, J = 9.1 Hz, 1H), 4.94 
(br s, 1H), 4.41–4.31 (m, 2H), 4.27–4.18 (m, 2H), 3.85 (s, 3H), 3.44–3.30 (m, 2H), 2.13–2.00 (m, 
2H), 1.43 (s, 9H). 13C NMR (100 MHz, CDCl3): δ 170.1, 167.2, 158.4, 144.7, 142.3, 128.4, 126.1, 
124.7, 119.1, 103.7, 79.5, 60.4, 52.5, 41.4, 37.7, 29.3, 28.4. ESI-MS m/z: calcd for C21H28N3O6 [M + 
H]+, 418.5; found, 418.3. 
tert-Butyl(S)-(3-((4-((2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)carbamoyl)quinolin-6-
yl)oxy)propyl)carbamate (7) 
Compound 5 (110 mg, 0.21 mmol) and LiOH (30 mg, 1.2 mmol) were stirred in 4 mL of H2O/THF 
(1/1) for 6 h. After most of the THF was removed under vacuum, the mixture was loaded onto a 25 g 
C18 cartridge and eluted with a MeCN/water/TFA gradient (0/100/0.1 to 90/10/0.1) to remove the 
salts. After removal of the solvent and drying, product 6 was obtained and mixed with (S)-pyrrolidine-
2-carbonitrile (53 mg, 0.4 mmol), HOBt (68 mg, 0.4 mmol), HBTU (152 mg, 0.4 mmol), and DIPEA 
(0.56 mL, 1.6 mmol) in dry DMF (10 mL). After 6 h, the solvent was removed under vacuum and the 
crude mixture was loaded onto a 25 g C18 cartridge (Silicycle, Canada). The product was purified 
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with a MeCN/water/TFA gradient (0/100/0.1 to 90/10/0.1). After lyophilization, 99 mg of 7 was 
obtained in an 80% yield. 1H NMR (400 MHz, CDCl3): δ 8.73 (s, 1H), 7.95 (d, J = 10.2 Hz, 1H), 7.68 
(br s, 1H), 7.63–7.56 (m, 1H), 7.56–7.48 (m, 1H), 7.38–7.29 (m, 1H), 5.27 (br s, 1H), 4.84–4.72 (m, 
1H), 4.46–4.35 (m, 1H), 4.33–4.20 (m, 1H), 4.17–4.09 (m, 2H), 3.78–3.64 (m, 1H), 3.59–3.46 (m, 
1H), 3.36 (s, 2H), 2.38–2.17 (m, 4H), 1.42 (s, 9H), 1.35–1.27 (m, 2H). 13C NMR (100 MHz, CDCl3): δ 
167.6, 167.5, 157.9, 156.2, 146.3, 130.2, 125.7, 123.7, 119.3, 118.0, 103.3, 79.0, 65.9, 46.8, 45.7, 






Compound 7 (1 mg, 1.7 μmol) was treated with a 1 mL solution of TFA/methylene chloride (1/1) for 2 
h. The solvent was removed under vacuum, and the remaining material was redissolved in 0.5 mL of 
DMF. To the solution, LI-COR IRdye 800CW-NHS ester (0.5 mg, 0.43 μmol) and DIPEA (10 μL) 
were added. After 2 h at ambient temperature, the solvent was removed and the product was 
purified by semi-preparative HPLC. 0.5 mg of the product was obtained in an 81% yield. HPLC 
conditions: Phenomenex, C18 Luna, 10μ, 10 mm × 250 mm column; gradient 90/10/0.1 to 80/20/0.1 
water/acetonitrile/TFA over 15 min at a flow of 3 mL/min. The product was eluted at 10.1 min. ESI-
MS m/z: calcd for C66H76N7O17S4+ [M + H]+, 1366.4; found, 1366.8. 
2,2′,2″-(10-(1-Carboxy-4-((3-((4-((2-((S)-2-cyanopyrrolidin-1-yl)-2-
oxoethyl)carbamoyl)quinolin-6-yl)oxy)propyl)amino)-4-oxobutyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetic Acid (QCP02) 
Compound 7 (15 mg, 31.3 μmol) was treated with a 1 mL solution of TFA/methylene chloride (1/1) 
for 1 h. The solvent was removed under vacuum, and the remaining material was re-dissolved in 0.5 
mL of DMF. To the solution, DIPEA (27 μL, 156.5 μmol) was added, followed by dropwise addition of 
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a solution of DOTA-GA(t-Bu)4-NHS (25 mg, 31.3 μL) in 0.5 mL of DMF. The reaction mixture was 
stirred for 4 h at ambient temperature and then concentrated under vacuum. The tert-Bu-protected 
intermediate was deprotected in situ without further purification using a 1 mL mixture of TFA, H2O, 
and triethylsilane (TES) (95:2.5:2.5). The reaction mixture was then concentrated and purified by 
semi-preparative HPLC to afford the product as a white solid (8.5 mg, 33% yield). HPLC conditions: 
Phenomenex, C18 Luna, 10μ, 10 mm × 250 mm column; mobile phase 95/5/0.1 to 75/25/0.1% 
water/acetonitrile/TFA over 20 min; flow 5 mL/min. QCP02 was eluted at 11.8 min. HRMS (ESI) m/z: 
calcd for C39H54N9O12 [M + H]+, 840.3892; found, 840.3885. 
113/115Indium(III) 2,2′,2″-(10-(1-Carboxy-4-((3-((4-((2-((S)-2-cyanopyrrolidin-1-yl)-2-
oxoethyl) carbamoyl)quinolin-6-yl)oxy)propyl) amino)-4-oxobutyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl) Triacetate ([In]QCP02) 
To a solution of 2 mg (2.4 μmol) of QCP02 in 1 mL of aqueous 0.2 M sodium acetate, a solution of 
In(NO3)3 (1.4 mg, 4.6 μmol) in 0.5 mL of water was added and warmed in a 60 °C bath for 30 min. 
After cooling to ambient temperature, the mixture was purified by semi-preparative HPLC. The 
product was obtained as a white solid (1.8 mg, 79% yield). ESI-MS m/z: calcd for C39H51N9O12In [M 
+ H]+, 952.7; found, 952.5. HPLC conditions: Phenomenex, C18 Luna, 10μ, 10 mm × 250 mm 
column; mobile phase 95/5/0.1 to 75/25/0.1 water/acetonitrile/TFA over 20 min; flow 5 mL/min. 




Briefly, a 20 μg QCP02 solution in 20 μL of 0.2 M NaOAc was added to 10 μL of 170.2 MBq 111InCl3 
solution in 0.05 N HCl and adjusted to a final pH of 5.5–6. The mixture was heated in a water bath at 
70 °C for 30 min and then diluted with 200 μL of water for HPLC purification. The solution was 
purified using a Phenomenex, C18 Luna, 5μ, 4.6 mm × 250 mm column (Torrance, CA) with a flow 
rate of 0.6 mL/min with water (0.1% TFA) (A) and MeCN (0.1% TFA) (B) as the eluting solvents. An 
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isocratic solution of 88% A and 12% B was utilized for purification, resulting in [111In]QCP02, eluting 
at 19.3 min, followed by QCP02 at 21.3 min. 118.4 MBq of the labeled compound was obtained in 
yields between 69 and 74%. The radiochemical purity was >95% as measured by HPLC. The 
obtained radioactivity was diluted with 20 mL of water and loaded onto activated Sep-Pak 
(WAT020515, Waters, Milford, MA). After the Sep-Pak was washed with 10 mL of water, 
[111In]QCP02 was eluted with 1.5 mL of ethanol. The ethanol was evaporated under a gentle stream 
of nitrogen (to a total volume of <50 μL) and diluted with saline to reduce the ethanol percentage to 
<10% for imaging and biodistribution studies. 
FAP Inhibition Assay 
The inhibitory activities of QCP01 and [113/115In]QCP02 were determined using a fluorogenic FAP 
Assay Kit (BPS Bioscience, San Diego, CA). Briefly, the test compound (QCP01: 50–0.39 nM, 
[113/115In]QCP02: 500–0.23 nM), the reactive substrate, and human recombinant FAP were loaded 
into a 96-well plate to initiate the enzymatic reaction. The reaction was left for 10 min at RT before 
the fluorescence was measured for 0.1 s per well with a VICTOR3 V multilabel plate reader 
(PerkinElmer Inc., Waltham, MA) at an excitation wavelength of 355 nm and an emission wavelength 
of 460 nm. Data were normalized, and semi-log inhibition curves were generated in order to 
determine the half-maximal inhibitory concentrations (IC50 values) and subsequent enzyme inhibition 
constants (Ki) using the Cheng–Prusoff conversion71. Generation of semi-log inhibition curves and 
IC50 values was performed using GraphPad Prism software (San Diego, CA). 
Analysis of the CCLE Database and TCGA Data 
Messenger RNA (mRNA) expression data of FAP in human cell lines, generated by RNAseq 
analysis, were downloaded (9/17/19) from the CCLE database72 and sorted by cell line “type”. All 
samples with no type or FAP measurement were excluded. Z-Scores were calculated using all cell 
lines as a reference, and samples were grouped by cancer cell type for visualization. To evaluate 
FAP expression in normal tissues and human tumors, pan-cancer normalized FAP RNAseq (Illumina 
HiSeq) gene expressions in normal tissues and primary tumors (downloaded 9/20/19) were 
25 
 
downloaded (10/22/19) for 18 TCGA cohorts and 32 TCGA cohorts, respectively, using the UCSC 
Xena platform73. 
Cell Lines 
U87, SKMEL24, and NCIH2228 cell lines were identified from the CCLE as having high levels of 
FAP expression [FAP-positive (+)], whereas PC3, NCIH226, and HCT116 cells expressed very low 
levels of FAP [FAP-negative (−)]. FAP expression was further confirmed by flow cytometry with 10 
μL of an allophycocyanin-conjugated anti-FAP antibody (Clone #427819, R&D Systems, 
Minneapolis, MN) and quantitative real-time polymerase chain reaction. All cell lines were purchased 
from American Type Culture Collection (ATCC, Manassas, VA). 
 
Binding of imaging agents to FAP was assessed in six human cancer cell lines of different cancer 
types: glioblastoma (U87), melanoma (SKMEL24), prostate (PC3), NSCLC (NCIH2228), colorectal 
carcinoma (HCT116), and lung squamous cell carcinoma (NCIH226). 
 
U87 cells were maintained in the minimum essential medium (MEM) (Corning Cellgro, Manassas, 
VA), containing 10% fetal bovine serum (FBS) (Sigma-Aldrich, St. Louis, MO) and 1% penicillin–
streptomycin (Corning Cellgro), supplemented with sodium bicarbonate (Corning Cellgro), sodium 
pyruvate (Gibco, Gaithersburg, MD), and MEM non-essential amino acids (Gibco). SKMEL24 cells 
were maintained in MEM, containing 15% FBS and 1% penicillin–streptomycin, supplemented with 
sodium bicarbonate, sodium pyruvate, and MEM non-essential amino acids. PC3 cells were grown 
in Ham’s F-12K medium (Corning Cellgro), supplemented with 10% FBS and 1% penicillin–
streptomycin. NCIH2228, NCIH226, and HCT116 cells were cultured in the RPMI 1640 medium 
(Corning Cellgro), supplemented with 10% FBS and 1% penicillin–streptomycin. Cell cultures were 
maintained at 37 °C and 5% carbon dioxide (CO2) in a humidified incubator. 
Cellular Uptake Studies 
For in vitro studies, cells were detached using 0.05% trypsin (Corning), re-suspended in 1 million cell 
aliquots in the binding buffer (1× PBS with 2 mM EDTA and 0.5% FBS), and incubated with various 
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concentrations (range: 50–0.78 nM) of QCP01 for 1 h in the incubator. To assess specific uptake of 
QCP01, cells were preblocked with an FAP- and DPP-IV-specific inhibitor, Val-boroPro (Millipore 
Sigma, Burlington, MA), or a DPP-IV-specific inhibitor, sitagliptin (Santa Cruz Biotechnology, Inc., 
Dallas, TX), at various concentrations (range: 10–10 to 10–4 M). This was followed by incubation with 
25 nM QCP01 in the binding buffer for 1 h at 37 °C, and cellular uptake was terminated by washing 
cells with ice cold PBS (1×) three times. Cells were re-suspended in the binding buffer and 
transferred to a 96-well plate for imaging. Images were obtained on the LI-COR Pearl Impulse 
Imager (Lincoln, NE) using an excitation wavelength of 785 nm and detection of the emission 
wavelength at 800 nm. Images were analyzed using LI-COR Pearl Impulse Software (Version 2.0), 
and the fluorescence intensity was corrected for the background signal and normalized to the well 
area. 
 
Cellular uptake of [111In]QCP02 was assessed by incubating cell aliquots (1 million) with 0.037 MBq 
[111In]QCP02 in saline for 30 min at 37 °C. Cells were washed three times with cold PBS (1×), and 
the radioactivity of the cell pellets was measured with a 1282 CompuGamma CS gamma well 
counter (Pharmacia/LKB Nuclear, Inc., Gaithersberg, MD). The cellular uptake is presented as a 
percent of incubated activity measured using sample aliquots. All cellular uptake and binding studies 
were performed in triplicate and repeated three times. 
Mouse Xenograft Models 
Animal studies were performed according to protocols approved by the Johns Hopkins University 
Animal Use and Care Committee. Male NOD/SCID mice, 6–8 weeks old, were purchased from the 
Johns Hopkins Immune Compromised Animal Core (Baltimore, MD). NOD/SCID mice were 
subcutaneously inoculated in the upper left and right flanks with 1 million FAP-positive U87 and 
FAP-negative PC3 cells in Hank’s balanced salt solution (HBSS), respectively. Mice were monitored 




Small-Animal NIRF Imaging 
NIRF images were obtained on the LI-COR Pearl Impulse Imager using an excitation wavelength of 
785 nm and a detection wavelength of 800 nm. Mice utilized for imaging studies were anesthetized 
with 3% isoflurane (v/v) and maintained at 1.5% isoflurane for the imaging procedure. NOD/SCID 
mice bearing U87 and PC3 tumor xenografts were injected with 5 nmol of QCP01via the tail vein, 
and images were obtained at 0.5, 1.5, 2.5, 5, 24, and 48 h post injection. Mice were sacrificed at 
various time points, and whole body images were obtained. Following this, organs of interest were 
harvested and imaged ex vivo on a Petri dish. Data were displayed and analyzed using LI-COR 
Pearl Impulse Software (Version 2.0). 
Small-Animal SPECT-CT Imaging 
For imaging studies, mice were induced with 3% isoflurane anesthesia and maintained at 1.5%. 
After mice were injected with 7.4 MBq [111In]QCP02 in 200 μL of saline, SPECT-CT imaging was 
carried out using a CT-equipped Gamma Medica-Ideas SPECT scanner (Northridge, CA) at the 
designated time points (1, 3, 6, 10, and 28 h) after [111In]QCP02 injection. A CT scan was performed 
at the end of each SPECT scan for anatomic co-registration. Obtained data sets were reconstructed 
using the provided Gamma Medica-Ideas software for final data visualization. Volume-rendered 
images were prepared using Amira 5.3.3 software (Visage Imaging, Inc., San Diego, CA). 
Biodistribution 
NOD/SCID mice bearing U87 and PC3 tumor xenografts were injected via the tail vein with 0.37 
MBq [111In]QCP02 in 200 μL of saline. At 5 min, 30 min, 1 h, 3 h, 6 h, 10 h, and 28 h post injection, 
mice (n = 4) were sacrificed by CO2 asphyxiation and blood was immediately collected by cardiac 
puncture. Additionally, the heart, lungs, liver, stomach, pancreas, spleen, fat, kidney, small intestine, 
large intestine, bladder, muscle, femur, and U87 and PC3 xenografts were collected for analysis. 
Each tissue was weighed, and the radioactivity was measured using an automated gamma counter. 
Radioactivity measurements were corrected for decay and compared with samples of a standard 
dilution of the initial dose to calculate the percentage injected dose per gram of tissue (% ID/g). For 
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blocking studies, mice (n = 4) were co-injected with non-radiolabeled QCP02 (50 μg per mouse) and 
0.37 MBq [111In]QCP02 in 200 μL of saline via the tail vein. At 6 h post injection, mice were 
sacrificed, tissues were collected, and the radioactivity was measured with the gamma counter. 
Data Analysis 
Data are expressed as mean ± standard deviation. Prism software (GraphPAD, San Diego, CA) was 
used for analysis, and the statistical significance was calculated using a two-tailed Student’s t-test. A 










Figure 2-2. Chemical Synthesis of QCP01 and QCP02a 
aReagents and conditions: (a) glycine methyl ester hydrochloride, HOBt, HBTU, iPr2NEt, DMF, RT, 6 h, 76%; (b) 3-(Boc-
amino) propyl bromide, Cs2CO3, DMF, RT, 16 h, 54%; (c) LiOH, H2O/THF, RT, 6 h, 99%; (d) (S)-pyrrolidine-2-carbonitrile 
hydrochloride, HOBt, HBTU, iPr2NEt, DMF, RT, 6 h, 80%; (e) TFA/CH2Cl2, RT, 1 h; (f) IRDye 800CW-NHS ester, iPr2NEt, 





Figure 2-3. FAP expression in human cancers. 
FAP mRNA expression in human cancer cell lines from the CCLE (A) and in human primary tumors from TCGA (B) was 
analyzed. FAP mRNA expression in primary tumors and normal tissues from TCGA data was also analyzed (C); NSCLC = 
non-small-cell lung cancer; SCLC = small-cell lung cancer; DLBCL = diffuse large B-cell lymphoma; AML = acute myeloid 
leukemia; CML = chronic myelogenous leukemia; PAAD = pancreatic cancer; BRCA = breast cancer; MESO = 
mesothelioma; HNSC = head and neck cancer; LUAD = lung adenocarcinoma; LUSC = lung squamous cell carcinoma; 
STAD = stomach cancer; UCS = uterine carcinosarcoma; ESCA = esophageal cancer; READ = rectal cancer; DLBC = large-
B-cell lymphoma; COAD = colon cancer; SKCM = melanoma; CHOL = bile duct cancer; BLCA = bladder cancer; CESC = 
32 
 
cervical cancer; UCEC = endometrioid cancer; OV = ovarian cancer; KIRC = kidney clear cell carcinoma; TGCT = testicular 
cancer; THCA = thyroid cancer; GBM = glioblastoma; PRAD = prostate cancer; ACC = adrenocortical cancer; PCPG = 
pheochomocytoma; LIHC = liver cancer; LGG = lower-grade glioma; KIRP = kidney papillary cell carcinoma; UVM = ocular 





Figure 2-4. In vitro binding and specificity of QCP01 and [111In]QCP02. 
(A) Cells incubated with various concentrations (range: 50–0.78 nM) of QCP01 were imaged with the LI-COR Pearl Impulse 
Imager to assess binding of the agent in various FAP-positive (+) and FAP-negative (−) cell lines (left). Dose–response 
curves of QCP01 binding in FAP-positive cell lines (NCIH2228, U87, and SKMEL24) and FAP-negative cell lines (PC3, 
NCIH226, and HCT116) were generated (right). (B) Cells were incubated with 0.037 MBq [111In]QCP02 and were washed 
with cold phosphate-buffered saline (PBS). The radioactivity of the cell pellets was measured and normalized to the 
incubated dose; ****, P < 0.0001. (C) Cells incubated with 25 nM QCP01 were incubated with various concentrations of 
either a DPP-IV and FAP inhibitor, Val-boroPro, or a DPPIV-only inhibitor, sitagliptin. The binding of QCP01 was measured, 





Figure 2-5. NIRF imaging of QCP01 in a tumor-bearing mouse. 
NOD/SCID mice bearing FAP-positive U87 (red) and FAP-negative PC3 (white) tumor xenografts (n = 4) were injected with 
5 nmol of QCP01via the tail vein, followed by serial NIRF imaging on the LI-COR Pearl Impulse Imager. Representative 
images of QCP01 full body (left) distribution at 5 h after injection and organ-specific (right) distribution at 5, 24, and 48 h 





Figure 2-6. Serial SPECT-CT imaging of [111In]QCP02 in a tumor-bearing mouse. 
A NOD/SCID mouse bearing FAP-positive U87 (red) and FAP-negative PC3 (blue) tumor xenografts was injected with 7.4 
MBq [111In]QCP02 via the tail vein, followed by serial SPECT-CT imaging. Representative three-dimensional SPECT-CT 




(A) HPLC Analysis of QCP02 
 
(B) HPLC Analysis of [113/115In]QCP02 
 
(C) Radio-HPLC analysis of [111In]QCP02 
 
(D) HPLC and radio-HPLC analyses of spiked [113/115In]QCP02 and [111In]QCP02 
 
 
Supplemental Figure 2-1. (A) HPLC chromatogram of QCP02 and (B) radio-HPLC chromatogram of [111In]QCP02. 
HPLC purification was performed on an Agilent PrepStar system, equipped with a Agilent ProStar 325 UV-vis variable 
wavelength detector and a Bioscan Flow-count in-line radioactivity detector. The compounds were purified using a 
Phenomenex, C18 Luna, 5µ, 4.6 mm × 250 mm column with a flow rate of 0.6 mL/min with water (0.1% TFA) (A) and MeCN 
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(0.1% TFA) (B) as the eluting solvents. An isocratic solution of 88% A and 12% B was used for purification, resulting in 
QCP02 eluting at 21.3 min (detection wavelength 254 nm), and [113/115In]QCP02 and/or [111In]QCP02 eluting at 19.3 min 
(detection wavelength 254 nm). Free 111In elutes at 5 to 7 min. HPLC purification removes non-chelated precursor, enabling 





Supplemental Figure 2-2. Inhibitory activity of QCP01 and [113/115In]QCP02 on human recombinant FAP. 
Inhibitory activity of QCP01 (A) and [113/115In]QCP02 (B) was determined using a fluorogenic FAP assay kit. Semi-log 
inhibitory curves of QCP01 and [113/115In]QCP02 activity were generated and the determined Ki values were 1.26 nM (95% 





Supplemental Figure 2-3. FAP surface expression in FAP-positive and FAP-negative cell lines. 
FAP surface expression on cancer cell lines were confirmed via flow cytometry. Cells incubated with anti-FAP antibody are 





Supplemental Figure 2-4. FAP mRNA expression in metastatic and primary tumor human melanoma (SKCM) samples 
























Supplemental Figure 2-5. Serial NIRF imaging of QCP01 in tumor bearing mice. 
NOD/SCID mice bearing FAP-positive U87 (red) and FAP-negative PC3 (white) tumor xenografts (n=4) were injected with 5 
nmols of QCP01 via the tail vein followed by serial NIRF-imaging on the LI-COR Pearl Impulse Imager. Representative 




Supplemental Table 2-1. Ex vivo biodistribution of [111In]QCP02 in tumor bearing mice. 
 
Results are expressed as mean percentage injected dose per gram (%ID/g) of tissue ± standard deviation. 
*Comparison of mean %ID/g of PC3 tumor versus U87 tumor (* , P < 0.05; ** , P < 0.001; *** , P < 0.0001). 




Chapter 3: Examining brain inflammatory processes 
through kinetic modeling of radiotracers in human clinical 
studies: A first in human study of [18F]FNDP 
Summary: 
The focus of this chapter is on the use of [18]FNDP to study the distribution of soluble epoxide 
hydrolase (sEH) in the human brain. In this first in man study, we utilized positron emission 
tomography to study the distribution of [18F]FNDP in 7 healthy human subjects. Using PMOD, we 
were able to use the time activity curves generated for the 10 regions of interest (ROIs) to 
characterize the binding of [18F]FNDP to sEH using a two-tissue compartment model and Logan 
graphical analysis. We observed that binding of [18F]FNDP was higher in human cerebellar cortex 
and thalamus relative to supratentorial cortical regions, aligning with the reported expression of sEH 




First-in-human neuroimaging of soluble epoxide hydrolase using 
[18F]FNDP PET 
 
This work has been published and is reprinted here with permission from the European Journal of 
Nuclear Medicine and Molecular Imaging. 
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Minn I, Rowe SP, Dannals RF, Horti AG, Pomper MG. First-in-human neuroimaging of soluble 





Soluble epoxide hydrolase (sEH) is an enzyme with putative effect on neuroinflammation through its 
influence on the homeostasis of polyunsaturated fatty acids and related byproducts. sEH is an 
enzyme that metabolizes anti-inflammatory epoxy fatty acids to the corresponding, relatively inert 
1,2-diols. A high availability or activity of sEH promotes vasoconstriction and inflammation in local 
tissues that may be linked to neuropsychiatric diseases. We developed [18F]FNDP to study sEH in 
vivo with positron emission tomography (PET). 
Methods 
Brain PET using bolus injection of [18F]FNDP followed by emission imaging lasting 90 or 180 min 
was completed in healthy adults (5 males, 2 females, ages 40–53 years). The kinetic behavior of 
[18F]FNDP was evaluated using a radiometabolite-corrected arterial plasma input function with 




[ 18F]FNDP PET was without adverse effects. Akaike information criterion favored the two-tissue 
compartment model (2TCM) in all ten regions of interest. Regional total distribution volume (VT) 
values from each compartmental model and Logan analysis were generally well identified except for 
corpus callosum VT using the 2TCM. Logan analysis was assessed as the choice model due to 
stability of regional VT values from 90-min data and due to high correlation of Logan-derived regional 
VT values with those from the 2TCM. [18F]FNDP binding was higher in human cerebellar cortex and 
thalamus relative to supratentorial cortical regions, which aligns with reported expression patterns of 
the epoxide hydrolase 2 gene in human brain. 
Conclusion 
These data support further use of [18F]FNDP PET to study sEH in human brain. 
 
Introduction 
Soluble epoxide hydrolase (sEH) is an enzyme expressed throughout the body, and plays a role in 
maintaining homeostasis of polyunsaturated fatty acids and their byproducts. That homeostasis may 
have an effect on immune signaling, as reviewed by Zarriello et al.28 For example, polyunsaturated 
fatty acids can be metabolized to epoxy fatty acids (epoxyeicosatrienoic or epoxydocosapentaenoic 
acids) that promote vasodilatation and anti-inflammatory pathways, while the metabolism of 
polyunsaturated fatty acids through the cyclooxygenase pathway yields more inflammatory 
derivatives (prostaglandins). Since sEH is an enzyme that metabolizes anti-inflammatory epoxy fatty 
acids to the corresponding, relatively inert 1,2-diols, a high availability or activity of sEH may 
promote vasoconstriction and inflammation in local tissues28,74. That inflammatory microenvironment 
may foster and/or exacerbate pathologic changes in several clinical conditions75,76, and therapies to 




We developed N-(3,3-diphenylpropyl)-6-18F-fluoronicotinamide ([18F]FNDP) (Figure 3-1) for use with 
positron emission tomography (PET) to study the proposed link between high availability of sEH in 
the human brain and neurologic or psychiatric conditions75,76. [18F]FNDP PET may also provide utility 
in assessing target engagement of drugs developed to block sEH activity in brain. [18F]FNDP 
showed high binding specificity in CD-1 and sEH knockout mice77. In brains of Papio anubis, 
[18F]FNDP demonstrated reversible radiotracer pharmacokinetics and [18F]FNDP binding [total 
distribution volume (VT)] was estimated well in 18 regions of interest (ROIs) using 90-min dynamic 
emission data with a radiometabolite-corrected arterial input function77. HPLC radiometabolite 
analyses in CD-1 mouse and baboon studies demonstrated evidence of two radiometabolites of 
[18F]FNDP (parent [18F]FNDP, retention time = 7.8 min; metabolite #1, retention time = 1–2 min; 
metabolite #2, retention time = 5.7 min). Sacrifice of the mice at 10 and 30 min post-injection (p.i.) of 
[18F]FNDP revealed only a small (1.7%) presence of metabolite #1 in the brain at 30 min p.i., and no 
brain penetration of metabolite #278. In baboon brains, [18F]FNDP VT was highest in insula, putamen, 
caudate, and amygdala, and intermediate in frontal and temporal cortices, as well as 
hippocampus77,78. Globus pallidus, white matter, hypothalamus, and thalamus had relatively lower 
[18F]FNDP VT estimates, and lowest [18F]FNDP VT occurred in cerebellum77,78. Pre-PET 
pharmacological treatment with a sEH inhibitor (nor-fluoro-FNDP) resulted in 95% blockade of the 
[18F]FNDP binding in baboon brain77. Dose-dependent blockade in baboon brain was also found 
using AR-9281, a sEH inhibitor that is structurally dissimilar to FNDP78. Together, these blocking 
studies support high binding specificity of [18F]FNDP. 
 
Here, we report the first use of [18F]FNDP PET in the healthy human brain. Since there are no known 
brain regions without sEH, quantitative binding was estimated using [18F]FNDP imaging data with an 
arterial input function. 
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Materials and Methods 
Human subject participation 
This prospective study was approved by a Johns Hopkins Institutional Review Board. Healthy 
individuals between the ages of 35–55 years were recruited through local advertising and provided 
written, informed consent. Each subject completed a screening interview and blood work, 
electrocardiogram, and urine toxicology. Eligible participants were in stable health, with no clinical 
abnormality on the screening assessment or structural magnetic resonance imaging (MRI). 
Exclusion criteria included past neurological or psychiatric illness, history of substance abuse 
including marijuana (assessed by self-report and urine toxicology), recent infection, past head 
trauma with loss of consciousness, contraindication to MRI, or contraindication to PET with arterial 
line. 
[18F]FNDP PET in humans 
Synthesis and injection of [18F]FNDP 
[18F]FNDP was synthesized as previously described79 and radiochemical purity was >95% at the end 
of each synthesis. 
Brain PET image acquisition 
PET data were acquired on a CPS/CTI High Resolution Research Tomograph (CPS Innovations, 
Inc., Knoxville, TN). Prior to scanning, a thermoplastic mask was molded to the participant’s face for 
head fixation. A radial arterial catheter was placed for arterial blood sampling, and an intravenous 
catheter was inserted for radiotracer administration. A transmission scan was performed prior to the 
emission scan that began with bolus injection of [18F]FNDP. Continuous emission data were 
collected for 180 min (N = 3) or 90 min (N = 4) p.i. 
 
The PET data were binned into 30 frames (90-min scans, N = 4) or 48 frames (180-min scans, N = 
3): 4 × 15 s, 4 × 30 s, 3 × 1 min, 2 × 2 min, 5 × 4 min, and 12 × or 30 × 5-min frames. Those data 
were reconstructed using the ordinary Poisson variant of the 3D ordered subsets expectation 
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maximization algorithm (with six iterations and 16 subsets)80, without point spread function modeling, 
and with 2 mm Gaussian filtering. Each reconstructed image was 256 × 256 × 207 voxels, with voxel 
size: 1.22 × 1.22 × 1.22 mm3. 
Plasma analysis 
Approximately 30–35 arterial blood samples (each 1 mL) were collected p.i. at the following time 
points: as fast as possible over 1.5 min; every 30 s between 1.5 and 3 min; every 2 min between 3 
and 5 min; and every 5 min between 5 min to the end of the emission scan. Plasma was isolated by 
centrifugation at 4 °C (5 min at 2200 g) and radioactivity was counted using a 2480 WIZARD2 
gamma counter (PerkinElmer, Waltham, MA). 
 
Larger (~4–6 mL) blood samples for analysis of parent [18F]FNDP and its radiometabolites occurred 
at the following time points: before [18F]FNDP injection for background measure, and p.i. at 5, 10, 20, 
30, 45, 60, 75, and 90 min. Additional blood samples were obtained at 105, 120, 150, and 180 min 
p.i. for emission scans lasting 180 min, with ~100 mL total arterial blood volume obtained from 
participants who underwent 180-min scan duration. Parent [18F]FNDP and its metabolites were 
analyzed using a reverse phase high-performance liquid chromatography (RP-HPLC) system 
composed of an Agilent Technologies (Santa Clara, CA) 1260 Infinity quaternary pump, a 1260 
Infinity column compartment module, a 1260 Infinity UV detector, and Raytest GABI Star radiation 
detectors controlled by OpenLab CDS EZChrom (A.01.04) software. The RP-HPLC system was first 
standardized using [18F]FNDP and a non-radioactive analog of the radiotracer prior to analysis. 
Plasma samples were loaded onto a 2-mL Rheodyne injector loop and directed to a capture column 
(packed with Phenomenex Strata-X 33-μm polymeric reverse phase sorbent) with 1% acetonitrile 
and 99% water mobile phase at 2 mL/min. The effluent from the capture column contained polar 
metabolites of [18F]FNDP directed to detectors. After 2 min of elution, an analytical mobile phase 
(65% acetonitrile, 35% aqueous 0.06-M ammonium formate) was applied to elute the trapped non-
polar metabolites and [18F]FNDP to an analytical column (4.6 × 250 mm, XBridge Column, 5 μm) at 
2 mL/min, which were then directed to detectors. RP-HPLC chromatograms were integrated to 
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provide percentage of parent [18F]FNDP relative to detected radiometabolite peaks at each time 
point. Metabolite-corrected plasma time-activity curves (TACs) were derived by applying the percent 
parent [18F]FNDP time-profiles from HPLC to the total plasma TACs after linear interpolation using 
PMOD (v3.7, PMOD Technologies Ltd., Zurich, Switzerland). 
 
Plasma-free fraction (fP) of [18F]FNDP was assessed using plasma isolated from blood sampling 
prior to radiotracer injection. Plasma (1 mL) was incubated with 0.37 MBq of [18F]FNDP for 5 min at 
room temperature. Then, three separate 150-μL aliquots of the mixture were applied to Centrifree 
membrane filters (Millipore, Burlington, MA) and centrifuged (20 min, 26,000g, 25 °C). To calculate 
fP, 50-uL samples of elute and three 50-μL samples of plasma incubated with [18F]FNDP were 
counted on an automated gamma counter (2480 WIZARD2 gamma counter (PerkinElmer, Waltham, 
MA), with fP = counts in ultrafiltrate relative to plasma. 
Brain MRI acquisition and regional segmentation 
Prior to PET, each participant completed a sagittal T1- weighted brain MRI sequence acquired using 
a 3 Tesla MAGNETOM Prisma scanner (Siemens, Malvern, PA, USA). Regions of interest (ROIs) 
were segmented from magnetization-prepared rapid gradient-echo data (spatial resolution 0.8 × 0.8 
× 0.8 mm3) using the FreeSurfer image analysis suite (http://surfer.nmr.mgh.harvard.edu/). The ten 
ROIs included a white matter region (corpus callosum), cortical regions (cerebellar, parietal, frontal, 
cingulate, occipital, and temporal cortices), and subcortical regions (thalamus, striatum, and 
hippocampus). 
Kinetic analysis 
PMOD was used for PET data processing and kinetic analyses, as well as pre-processing steps of 
motion correction and co-registration of PET and MRI data. Interframe motion correction was 
completed by rigid realignment of all frames of the reconstructed image to the 0–30-min mean PET 
image that was obtained by averaging frames 1 through 18. The 0–30-min mean image, and 
subsequently all motion-corrected PET frames, were co-registered to the individual’s T1-weighted 
MRI using rigid transformations. Regional TACs were generated after applying the above ROIs to 
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the dynamic PET data that were transformed into MR space. Regional VT81 values were derived 
using the radiometabolite-corrected arterial input function with the one- or two-tissue compartment 
model (1TCM, 2TCM), or Logan graphical analysis82. Logan-derived VT values were first evaluated 
using unfixed t* and allowing a maximum error criterion of 10%, which guided the choice of fixed t* 
=30 min (Supplemental Figure 3-1). For 1TCM and 2TCM, cerebral blood volume was set at 5% of 
brain volume when accounting for activity in the vasculature. 
 
Model choice (1TCM v. 2TCM) was evaluated based on goodness of fit using the Akaike Information 
Criterion (AIC) and F-test83,84. The identifiability of VT and other rate constants was assessed using 
the percent standard error from the theoretical parameter covariance matrix. Values assessed as 
identified “well” met criteria of % SE < 10%. For the three individuals with 180-min scans, regional VT 
values were evaluated using varied, shortened scan durations down to 90-min data. In these 
analyses, VT values derived from 180-min data were used as the standard for comparison. For each 
shortened scan duration (X), the relative bias values were expressed as |𝑉𝑇 𝑋 𝑚𝑖𝑛 − 𝑉𝑇 180 𝑚𝑖𝑛|/
𝑉𝑇 180 𝑚𝑖𝑛. 
 
In order to visualize VT of [18F]FNDP across the healthy brain, a VT parametric map was computed 
from the 90-min [18F]FNDP dynamic PET data using Logan analysis (t* = 30 min, N = 7) with the 
metabolite-corrected plasma input function. The VT maps were then normalized using the PMOD’s 
human brain normalization template derived from Statistical Parametric Mapping software (SPM8; 
Wellcome Centre for Human neuroimaging, UCL, London) and averaged to generate a mean VT 
parametric map. 
Statistical analysis 
Microsoft Excel (Microsoft 365) was used for statistical analyses. Quantitative results are presented 
as mean ± standard deviation (SD) unless otherwise noted. The correlation between continuous VT 
values derived from different approaches (1TCM, 2TCM, Logan graphical analysis) was evaluated 




Radiotracer injection and plasma analysis 
Seven participants (5 males, 2 females, ages 40–53 years, median 52 years) underwent [18F]FNDP 
PET (Table 3-1). Molar radioactivity was 1592 ± 1289 GBq/μmol (range 466– 4025 GBq/μmol) at the 
time of injection. The mean administered mass and radioactivity of [18F]FNDP were 0.13 ± 0.09 μg 
(range 0.03–0.26 μg) and 355.7 ± 25.6 MBq (range 309.0–378.1 MBq), respectively. Injection of 
[18F]FNDP did not yield adverse effects and there were no clinical changes in pre- versus post-
injection laboratory (blood, electrocardiogram) results. 
 
Plasma activity peaked within 90 s p.i. and decreased to <5% of the peak by 5 min (Figure 3-2a for 
representative curve). The mean parent fraction at 180 min p.i. (N = 3) was 16.6 ± 6.5%, and at 90 
min p.i. (N = 7, Figure 3-2b) was 27.2 ± 6.9%. fP was 1.5 ± 0.2% (N = 7). Radio-RP-HPLC 
chromatograms recorded for the plasma collected at 180 min post-injection of [18F]FNDP showed 
elution of (1) a polar radiometabolite species not retained on the capture column, (2) a 
radiometabolite that was retained on the capture column, and (3) parent [18F]FNDP that is more 
lipophilic than species #2 as demonstrated by ~2 min longer retention time (Figure 3-2c). 
Modeling results 
[18F]FNDP uptake across the brain ROIs is shown in Figure 3-3. TACs in corpus callosum peaked 
earlier (~2.5–3.5 min) compared to other regions that peaked ~7 min. Highest peak radioactivity 
concentration (standardized uptake value, SUV) occurred in cerebellar cortex, and the lowest SUV 
peak was observed in corpus callosum. 
 
Visually, the 1TCM and 2TCM each fit the regional data well (Supplemental Figure 3-2). AIC favored 
the 2TCM in all ten ROIs (P < 0.001) (Supplemental Table 3-1). The F-test also confirmed that the 
2TCM showed significantly better fit (α = 0.05) compared to the 1TCM in 59 out of 70 TACs (84.3%). 
Overall, model selection criteria supported the 2TCM as preferred. Well-identified rate constants and 
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VT values from each compartmental model and Logan analysis are summarized in Table 3-2. The 
2TCM identified K1 and VT well for all ROIs except for VT in corpus callosum that had poor 
identifiability in four of seven participants, as well as VT in hippocampus and striatum in two separate 
individuals. Rate constants from the 2TCM other than K1 were moderately or poorly identified (with 
larger % SE) across all ten ROIs. The 1TCM identified well K1, k2, and VT for all ROIs. Using 90-min 
data (N = 7), VT values derived from each model (1TCM, 2TCM) and Logan graphical analysis were 
highest in cerebellar cortex, thalamus, striatum, and hippocampus, with intermediate VT values in 
other cortical ROIs, and lowest VT in corpus callosum. This pattern of high cerebellar binding is 
generally consistent with the reported expression pattern of the EPHX2 transcript (encoded by the 
gene for sEH) that is higher in cerebellum relative to hippocampus, thalamus, and cortex in human 
brain 85 (Supplemental Table 3-2). After excluding data from corpus callosum due to the relative, 
poor identifiability of VT, as well as the one case of poorly identified VT in each of hippocampus and 
striatum (Table 3-2), regional VT values were well correlated between each method: VT 2TCM = 1.07 
VT 1TCM - 0.08, R2 = 0.99; VT Logan, t* 30 min = 0.97 VT 2TCM + 0.02, R2 = 0.99; VT Logan, t* 30 min = 1.03 VT 
1TCM – 0.07, R2 = 0.99 (Supplemental Figure 3-3). Parametric images of Logan-derived VT from 90-
min emission data are shown in Figure 3-4. 
Time stability of VT 
Using data from the three healthy individuals with 180-min data, Logan-derived VT values from data 
shortened to 90 min were within 4% of the VT values obtained using the full 180-min data 
(Supplemental Figure 3-4). The minimum scan time needed to achieve stability in Logan-derived VT 
value for each ROI is listed in Supplemental Table 3-3. 
Discussion 
We present first human neuroimaging data that support further use of [18F]FNDP PET to estimate 
availability of sEH, which may be locally elevated in neuropsychiatric disorders including affective 
illness or schizophrenia75. [18F]FNDP PET was without adverse effects, and peak brain radioactivity 
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concentrations (SUV) ranged from ~2.4–3.4 for all ROIs except corpus callosum, which had a lower 
peak value (SUV ~1.5). 
 
Regional VT values were identified well using each model except when using the 2TCM to estimate 
VT in the corpus callosum. The 2TCM was favored over the 1TCM by AIC and the F-test. Using 
1TCM or 2TCM, K1 was identified well in all ROIs, and ranged between 0.14 and 0.19 mL cm−3 min−1 
in all regions except corpus callosum that had lower K1 (0.07 or 0.08 mL cm−3 min−1 using 1TCM or 
2TCM, respectively). Logan graphical analysis produced regional VTs that agreed with those 
estimated from both the 2TCM and 1TCM, supporting its use in computing VT in future [18F]FNDP 
PET studies. Time stability analysis indicated that a 90-min scan time is adequate for Logan 
graphical analysis to produce accurate regional VT values. 
 
VT values derived using each model were highest in cerebellar cortex, thalamus, and hippocampus 
(listed in sequentially decreasing order), across the ten ROIs that included five cortical brain regions. 
These human imaging data suggest a different pattern of sEH distribution in human brain compared 
to that of baboon, since we found evidence of relatively low sEH in baboon cerebellum using 
[18F]FNDP PET77,78. We note that our human imaging results are generally consistent with reported, 
higher consensus normalized expression levels of the epoxide hydrolase 2 gene (EPHX2) in human 
cerebellum, thalamus, and hippocampal formation compared to cerebral cortex85. We acknowledge 
that the scope of this work did not include the identification of the chemical structures of 
radiometabolite species. However, the pattern of decline after the single peak in the human time-
activity curves suggests an absence of brain-penetrant radiometabolites, and previous work using 
[18F]FNDP in mice revealed only minute (<2%) presence of a radiometabolite in brain78. Since 
binding in corpus callosum was relatively low, investigation of the degree of displaceable binding in 
this region should be studied further. Future work is also needed to evaluate for possible effects of 





[18F]FNDP PET is a promising technique for studying soluble epoxide hydrolase in human brain in 
vivo. These data support the use of Logan analysis to derive regional [18F]FNDP VT values using 90-










Figure 3-2. Plasma profile of parent [18F]FNDP and its radiometabolites in healthy individuals. 
a Total activity concentration (in SUV) in plasma and parent [18F]FNDP activity in plasma in a subject who underwent a 180-
min emission scan. b Fraction of parent [18F]FNDP in plasma over a 90-min emission scan (N = 7), shown as 
mean ± standard deviation. c Radio-RP-HPLC chromatogram recorded for the plasma collected at 180 min post-injection of 
[18F]FNDP, showing elution of (1) a polar radiometabolite species not retained on the capture column (26%); (2) a 
radiometabolite that was retained on the capture column (58%); and (3) parent [18F]FNDP (16%) that is more lipophilic than 




Figure 3-3. Regional radioactivity time-activity curves (TACs) in a representative healthy human participant.  





Figure 3-4. Mean parametric map of the total distribution volume (VT) of [18F]FNDP. 
For each of the healthy participants (N = 7), a VT parametric map was computed from the 90-min [18F]FNDP dynamic PET 
data using Logan analysis (t* = 30 min) with the metabolite-corrected plasma input function. The VT maps were then 




Table 3-1. Clinical characteristics of 7 healthy human participants. 
Age (years) 48.7 ± 4.9a 
Sex (Male/Female) 5/2 
Race (Caucasian/African American) 3/4 
Body mass index 28.0 ± 3.2a 




Table 3-2. Modeling of [18F]FNDP PET data from 90-min emission scans (N = 7) identified well the kinetic parameters and 
total distribution volume (VT) values using the one-tissue compartment model (1TCM) in all regions. 
K1 and VT values were well identified using a two-tissue compartment model (2TCM) in most regions, and VT values using 
Logan analysis were well identified in all regions 
 
Presented as mean ± standard deviation for each estimated parameter. Identifiability of each parameter was assessed as 




  1TCM 2TCM Logan 
ROI K1 k2 VT K1 k2 k3 k4 VT VT 
  (mL cm-3 min-1) (min-1) (mL cm-3) (mL cm-3 min-1) (min-1) (min-1) (min-1) (mL cm-3) (mL cm-3) 
Thalamus 0.17 ± 0.02 0.03 ± 0.01 6.15 ± 0.83 0.19 ± 0.03 0.07 ± 0.03 0.10 ± 0.06 0.07 ± 0.02 6.48 ± 0.93 6.30 ± 0.91 
Striatum 0.17 ± 0.02 0.03 ± 0.01 5.45 ± 0.68 0.18 ± 0.03 0.06 ± 0.03 0.06 ± 0.06 0.07 ± 0.04 5.72 ± 0.78a 5.49 ± 0.70 
Hippocampus 0.13 ± 0.02 0.02 ± 0.00 5.57 ± 0.81 0.15 ± 0.03 0.06 ± 0.03 0.07 ± 0.04 0.06 ± 0.03 5.98 ± 0.99a 5.79 ± 0.87 
Corpus Callosum 0.07 ± 0.01 0.02 ± 0.00 2.96 ± 0.47 0.08 ± 0.02 0.06 ± 0.02 0.05 ± 0.02 0.03 ± 0.01 3.24 ± 0.36b 3.34 ± 0.62 
Cerebellar CTX 0.17 ± 0.02 0.03 ± 0.00 6.59 ± 0.87 0.20 ± 0.03 0.08 ± 0.05 0.14 ± 0.14 0.07 ± 0.02 6.91 ± 0.94 6.70 ± 0.92 
Temporal CTX 0.14 ± 0.02 0.03 ± 0.01 4.32 ± 0.65 0.15 ± 0.03 0.07 ± 0.03 0.07 ± 0.08 0.06 ± 0.03 4.59 ± 0.73 4.41 ± 0.68 
Occipital CTX 0.18 ± 0.02 0.04 ± 0.01 4.60 ± 0.67 0.19 ± 0.03 0.08 ± 0.03 0.07 ± 0.06 0.07 ± 0.02 4.84 ± 0.71 4.73 ± 0.70 
Cingulate CTX 0.17 ± 0.02 0.04 ± 0.01 4.64 ± 0.66 0.18 ± 0.03 0.07 ± 0.04 0.07 ± 0.07 0.07 ± 0.03 4.88 ± 0.71 4.72 ± 0.72 
Frontal CTX 0.16 ± 0.02 0.04 ± 0.01 4.37 ± 0.57 0.18 ± 0.03 0.08 ± 0.04 0.09 ± 0.09 0.09 ± 0.04 4.54 ± 0.60 4.43 ± 0.61 




Supplemental Figure 3-1. Logan graphical analysis of healthy control data. 






Supplemental Figure 3-2. Typical time activity curve and model fits (1TCM, 2TCM) in cerebellar cortex from a 
representative individual. 





Supplemental Figure 3-3. Relationship between [18F]FNDP binding outcomes including comparison of A) 1TCM VT with 
2TCM VT; B) 2TCM VT with Logan VT; and C) 1TCM VT with Logan VT.  





Supplemental Figure 3-4. Assessment of the relative stability in [18F]FNDP regional Logan-derived total distribution volume 
(VT) values from 180 min of data compared to values produced from truncated (by five min intervals down to 90 min) scan 
duration (N=3). 
VT estimates are in units of mL cm-3. The percent of the absolute difference between the VT values from 180 minutes of data 




Supplemental Table 3-1. Comparison of the goodness of fit assessed by Akaike information criterion (AIC) values from 
each compartmental model applied to 90 min dynamic [18F]FNDP PET data from seven healthy human participants. 
ROI  1TCM*  2TCM* 
Thalamus  29.00 ± 15.21  10.00 ± 24.15 
Striatum  28.13 ± 11.81  21.07 ± 15.72 
Hippocampus  36.75 ± 14.19  23.88 ± 18.06 
Corpus 
Callosum  72.55 ± 7.67  67.00 ± 12.41 
Cerebellar CTX  26.00 ± 12.46  4.17 ± 25.03 
Temporal CTX  35.62 ± 13.82  23.66 ± 23.48 
Occipital CTX  33.12 ± 17.30  12.70 ± 27.43 
Cingulate CTX  38.24 ± 14.51  23.10 ± 27.24 
Frontal CTX  35.55 ± 16.64  20.68 ± 29.50 
Parietal CTX  34.56 ± 15.66  16.06 ± 29.25 
*AIC values are presented as mean ± standard deviation. Region of Interest, ROI; One-tissue compartment model, 1TCM; 




Supplemental Table 3-2. Among the regions of interest (ROIs) in this study, highest [18F]FNDP binding (VT) was found in 
cerebellar cortex, consistent with reported higher expression levels of EPHX2 in cerebellum relative to other ROIs evaluated.  






Cerebellar CTX 6.7 ± 0.9 5.6b 
Hippocampus 5.8 ± 0.9 4.1 
Thalamus 6.3 ± 0.9 3.9 
Cerebral CTX 4.6 ± 0.2c 3.3 
Logan graphical analysis used t* = 30 min. aUsing the online Human protein atlas 85, consensus normalized expression 
levels of the EPHX2 RNA transcript in brain are presented and were derived by combining data from two transcriptomics 
datasets. Of the 10 brain regions with consensus normalized expression levels, [18F]FNDP binding was assessed in four 
similar ROIs (listed). bThe human protein atlas reports data from total cerebellum, whereas the imaging study used 
cerebellar cortex.  c[18F]FNDP binding across cerebral cortex binding was derived by calculating the average of [18F]FNDP VT 




Supplemental Table 3-3. The minimum scan duration needed to achieve stable [18F]FNDP total distribution volume (VT) 
values using 180 min “gold-standard” duration (N = 3). 






Corpus Callosum 85 
Cerebellar Cortex 60 
Temporal Cortex 60 
Occipital Cortex 70 
Cingulate Cortex 60 
Frontal Cortex 60 
Parietal Cortex 60 
Stability of VT was assessed as < 5% absolute percent difference between [18F]FNDP VT derived from 180 min data and VT 




Chapter 4: Examining brain inflammatory processes 
through kinetic modeling of radiotracers in human clinical 
studies: A study of [18F]XTRA in extrathalamic regions 
Summary: 
The focus of this chapter is on the first in man study of [18F]XTRA to study the distribution of the 
α4β2 nicotinic acetylcholine receptor (α4β2-nAChR) in the human brain. In this study, we utilized 
positron emission tomography to study the distribution of [18F]XTRA in 17 healthy, non-smoking 
adults. Using PMOD, we were able to use the time activity curves generated for the 10 regions of 
interest (ROIs) to characterize the binding of [18F]XTRA to α4β2-nAChR using a two-tissue 
compartment model and Logan graphical analysis. Additionally, we used total distribution volumes 





18F-XTRA PET for enhanced imaging of the extrathalamic α4β2 nicotinic 
acetylcholine receptor 
 
This work has been published and is reprinted here with permission from The Journal of Nuclear 
Medicine. 
 
Coughlin JM, Slania S, Du Y, Rosenthal HB, Lesniak WG, Minn I, Smith GS, Dannals RF, Kuwabara 
H, Wong DF, Wang Y, Horti AG, Pomper MG. 18F-XTRA PET for Enhanced Imaging of the 




Reduced density of the α4β2 nicotinic acetylcholine receptor (α4β2-nAChR) in the cortex and 
hippocampus of the human brain has been reported in aging and patients with neurodegenerative 
disease. This study assessed the pharmacokinetic behavior of 18F-(−)-JHU86428 (18F-XTRA), a new 
radiotracer for in vivo PET imaging of the α4β2-nAChR, particularly in extrathalamic regions of 
interest in which the α4β2-nAChR is less densely expressed than in thalamus. 18F-XTRA was also 
used to evaluate the α4β2-nAChR in the hippocampus in human aging. 
Methods: 
Seventeen healthy nonsmoker adults (11 men, 6 women; age, 30–82 y) underwent PET 
neuroimaging over 90 or 180 min in a high-resolution research tomograph after bolus injection of 18F-
XTRA. Methods to quantify binding of 18F-XTRA to the α4β2-nAChR in the human brain were 




18F-XTRA rapidly entered the brain, and time–activity curves peaked within 10 min after injection for 
extrathalamic regions and at approximately 70 min in the thalamus. The 2-tissue-compartment 
model (2TCM) predicted the regional time–activity curves better than the 1-tissue-compartment 
model, and total distribution volume (VT) was well identified by the 2TCM in all ROIs. VT values 
estimated using Logan analysis with metabolite-corrected arterial input were highly correlated with 
those from the 2TCM in all regions, and values from 90-min scan duration were on average within 
5% of those values from 180 min of data. Parametric images of VT were consistent with the known 
distribution of the α4β2-nAChR across the brain. Finally, an inverse correlation between VT in the 
hippocampus and age was observed. 
Conclusion: 
Our results extend support for use of 18F-XTRA with 90 min of emission scanning in quantitative 
human neuroimaging of the extrathalamic α4β2-nAChR, including in studies of aging. 
 
Introduction 
Nicotinic acetylcholine receptors (nAChRs) are pentameric ligand–gated ion channels, of which the 
α4β2 and α7 are the most abundant subtypes in the human brain. The loss of activity of even a small 
quantity of neuronal nAChRs can have wide-ranging effects on neurotransmission across neural 
circuits86. Altered density of the α4β2-nAChR is linked to several neurodegenerative disorders26,87–89. 
Additionally, postmortem work using 3H-epibatidine90 and some in vivo human imaging, including 
that using 2-18F-fluoro-A-85380 (2-18F-FA) with PET89,91, suggest diminished availability of the α4β2-
nAChR in human aging. The binding of 2-18F-FA in the hippocampus and thalamus inversely 





There is need for α4β2-nAChR–targeting radiotracers with faster pharmacokinetics and high specific 
uptake in brain tissue outside the thalamus (extrathalamic regions such as the cortex and 
striatum)93,94, in which the α4β2-nAChR is less densely expressed95. 18F-(−)-JHU86428 (18F-
XTRA)96,97 is among such recently developed radioligands97–99 and has promising in vitro binding 
characteristics, including subnanomolar binding affinity (Ki = 0.06 nM) and improved lipophilicity 
(LogD7.4 = 0.67) over that of 2-18F-FA97. 18F-XTRA also showed stable, high binding estimates in 
extrathalamic regions of the baboon brain in vivo96. 
 
This study assessed use of 18F-XTRA with PET imaging in the human brain, particularly in 
extrathalamic regions of interest (ROIs). Estimates of total distribution volume (VT) generated using 
kinetic modeling methods with arterial input function and using alternative scan durations were 
compared. Finally, we investigated the correlation between age and VT in the hippocampus, a region 
in which low availability of the α4β2-nAChR may be linked to subtle deficits in cognition even in 
otherwise healthy older individuals92. 
Materials and Methods 
Human Subjects 
This prospective study was approved by a Johns Hopkins Institutional Review Board, and all 
subjects provided written informed consent. Seventeen healthy adult (≥18 y) participants were 
recruited through local advertising. Each subject completed a screening interview and laboratory 
testing (blood counts, metabolic panel, coagulation studies), electrocardiogram, and urine toxicology. 
Eligible participants had stable health with no clinical abnormality on the screening assessment and 
structural MRI. Exclusion criteria included nicotine use in the past year, past psychiatric or 
neurologic illness, history of substance abuse including marijuana (assessed by self-report and urine 
toxicology), medication known to affect acetylcholine signaling, current psychotropic medication use, 




All older (≥50 y) participants were also assessed with neuropsychologic testing that included the 
Clinical Dementia Rating scale100 to ensure a global Clinical Dementia Rating of 0, consistent with 
normal cognition. Since the apolipoprotein ε4 (APOE ε4) allele may play a role in aberrant 
cholinergic signaling101 that may be linked to altered α4β2-nAChR availability102, older participants 
were assessed for APOE ε4 carrier status using methods described previously103. 
Human Brain Imaging 
Synthesis of 18F-XTRA. 
18F-XTRA was synthesized as previously described96. Radiochemical purity was greater than 99%, 
with high specific radioactivity (1,586 ± 937 GBq/μmol) at the time of injection. The mean 
administered mass and radioactivity of 18F-XTRA were 0.08 ± 0.04 μg (range, 0.03–0.17 μg) and 
335 ± 38.3 MBq (range, 235–387 MBq), respectively. There were no adverse or clinically detectable 
pharmacologic effects, and no significant changes in vital signs, laboratory results, or 
electrocardiograms were observed. 
Brain PET Image Acquisition. 
All participants wore a thermoplastic facemask to minimize head movement and underwent both 
radial arterial line and antecubital venous catheter insertion. PET scans were acquired using a High-
Resolution Research Tomograph (Siemens Healthcare) with 2.5-mm reconstructed image 
resolution104. Each emission scan started at the time of bolus intravenous injection of 18F-XTRA, with 
continuous list-mode data collection for 90 (n = 10) or 180 (n = 7) min. Imaging data were 
reconstructed using methods described in the supplemental materials (available at 
http://jnm.snmjournals.org). 
Plasma Sampling. 
Measurement of the arterial plasma input function was conducted through collection of 35–50 blood 
samples (1 mL), obtained after injection using the previously published protocol103. Samples from 
120 to 180 min after injection were collected every 10 min. Plasma was immediately isolated from 
whole blood using centrifugation. Radioactivity was counted in a cross-calibrated γ-well-counter. The 
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fraction of parent radioligand in plasma was determined by high-performance liquid chromatography 
(HPLC) with blood sampling as previously described103, with additional blood sampling at 105, 120, 
150, and 180 min after injection for 180-min scans. 
 
The modified column-switching HPLC method105 used a Waters reverse phase XBridge BEH C18 5 
μM 4.6 × 150 mm analytic column, with an analytic mobile phase (45% acetonitrile and 55% 
aqueous solution of 0.1% ammonium hydroxide) at 2 mL/min. The HPLC system was standardized 
using nonradioactive XTRA and 18F-XTRA before analysis of plasma samples, which were spiked 
with 10 μL of XTRA (1 mg/mL) for each run. Metabolite-corrected plasma time–activity curves were 
obtained by applying percentage parent ligand time profiles, generated by HPLC analysis, to the 
total plasma time–activity curves after linear interpolation in PMOD (version 3.7; PMOD 
Technologies Ltd.). 
MRI Acquisition. 
T1-weighted brain MRI at 3 T was acquired for each participant using methods identical to those as 
previously described103, to obtain a 0.8 × 0.8 × 0.8 mm 3-dimensional image with a magnetization-
prepared rapid gradient-echo sequence. 
PET Image Analysis and Volumes of Interest. 
PET image processing, including motion correction and kinetic analysis, was conducted using 
PMOD as previously described103. PET time–activity curves were generated for 10 ROIs that were 
segmented from each MR image using the FreeSurfer image analysis suite 
(http://surfer.nmr.mgh.harvard.edu/). ROIs included the thalamus, striatum, hippocampus, corpus 
callosum, as well as cerebellar, temporal, occipital, cingulate, frontal, and parietal cortices. Total 
intracranial volume was also defined using FreeSurfer for generating regional volume ratio values 
(ROI volume normalized to total intracranial volume). 
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Derivation of Rate Constants and VTs. 
VT81 for each ROI was derived using the metabolite-corrected arterial input function and 
compartmental modeling (1-tissue-compartment model with 3 parameters [1TCM]; 2-tissue-
compartment model with 5 parameters [2TCM]) or Logan graphical analysis82. In compartmental 
modeling, nonlinear least-squares analysis was performed, with the Marquardt algorithm for 
parameter estimation106. Logan-derived VT values were determined using ordinary least squares 
after transformation of the PET data with t* = 45 min. The contribution of cerebral blood volume was 
set at 5% of brain volume. As in other recent PET imaging of this target96,107, reference-tissue 
models were not applied because there is no clearly identified human brain region devoid of the 
α4β2-nAChR. 
Statistics 
Compartmental model fitting was assessed by visual inspection of the model fit to the time–activity 
curves and by relative goodness of fit using the Akaike information criterion108. The standard errors 
of nonlinear least-square estimates of rate constants and VT from modeling were computed from the 
covariance matrix in PMOD and expressed as the coefficient of variation (% COV)109. Regional VT 
estimates from variable scan durations were evaluated using the 180-min acquisition as the 
reference for comparison of VT values from data shortening (shortened to 90 min). For each 
duration, denoted X, relative bias values were expressed as |VTX – VT 180 min|/VT 180 min. 
 
The relationship between VT in the hippocampus and age was tested using Spearman rank-order 
correlation analysis because age was not normally distributed across the study population. 
Secondary analyses testing the relationship between age and VT in the other 9 ROIs were also 
explored. 
 
Statistical analyses were performed using SPSS Statistics (version 23.0; IBM Corp.). Data were 
checked for outliers110, and descriptive statistics were obtained. Normality of the data was assessed 
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using the Shapiro–Wilk test. Data are presented as mean ± SD, and significance was set to a P 
value less than 0.05 unless otherwise noted. 
Results 
Human Subjects 
Seventeen healthy nonsmokers (11 men, 6 women; age, 30–82 y; median age, 60 y; interquartile 
range, 37 y) underwent PET neuroimaging with 18F-XTRA (Table 4-1). All older participants (n = 10) 
had a global Clinical Dementia Rating of 0, and none of the participants was an APOE ε4 carrier. 
ROI volumes and volume ratios from the study population are presented in Supplemental Table 4-1. 
Plasma Analysis 
Plasma activity peaked within 90 s after injection and decreased to less than 5% of the peak by 20 
min (Figure 4-1A). HPLC easily isolated 18F-XTRA (retention time, 7.5 min) from its radiolabeled 
metabolites, which were more polar and well resolved from the parent compound. 18F-XTRA 
represented 21.8% ± 10.7% of total plasma activity by 90 min (Supplemental Figure 4-1) and 15.2% 
± 10.5% by 180 min. 
Determination of VT 
18F-XTRA readily entered the brain and, for extrathalamic ROIs, activity peaked within 10 min after 
injection and then declined over the remaining 90- or 180-min scan duration (Figure 4-1B). Highest 
peak uptake occurred in the thalamus at approximately 70 min after injection except in 1 individual (a 
76-y-old Caucasian man) whose thalamic activity peaked just before the end of the 90-min emission 
scan. Activity in the thalamus washed out gradually after the peak. The lowest uptake was observed 
in the corpus callosum. 
 
Across the entire population, the kinetic behavior of 18F-XTRA over the 90-min scan in each ROI 
yielded a visually better fit using the 2TCM compared with the 1TCM (Figure 4-1C for representative 
data) except for within the thalamus of the aforementioned individual who had unusually late, 90-min 
peak thalamic activity that did not converge for either compartmental model. Those outlier data were 
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excluded from further analyses, and when all other 90 min of continuous data were used, the Akaike 
information criterion favored the 2TCM in all 10 ROIs (Supplemental Table 4-2). The 2TCM identified 
VT well (COV < 5%) for all ROIs except for the thalamus, which had a COV of 5.4% (Table 4-2). K1 
was also identified well (COV < 5%) using the 2TCM. The other rate constants from the 2TCM were 
identified with COV values of approximately 8%–22% for k2 and 9%–24% for k3/k4 across all 10 
ROIs. All VT estimates (compartmental modeling, Logan) using 90-min emission data were highest in 
the thalamus and were more homogeneous across regions of the striatum, hippocampus, and 
cortical ROIs. VT was lowest in the corpus callosum. 
 
When 90-min data were used, values of regional VT from Logan analysis correlated well with those 
of the 2TCM (Figure 4-2). Regional VT values generated using Logan analysis from the 90-min 
continuous scans were also within 5% of the VT values obtained using 180 min of continuous data 
from the same 7 individuals (Figure 4-3; Supplemental Table 4-3). Parametric images of VT derived 
using Logan analysis from 90-min emission scans demonstrated binding of 18F-XTRA throughout the 
brain (Figure 4-4). 
Correlation Between Age and VT in Hippocampus 
An inverse correlation between age and 18F-XTRA VT in hippocampus (rho = −0.589, P = 0.014) was 
found (Supplemental Figure 4-2). Secondary analyses revealed no significant correlation between 
age and VT in other ROIs after applying correction for multiple comparisons (P < 0.005 after 
Bonferroni adjustment for all 10 ROIs). There was also no correlation between body mass index and 
VT in any of the ROIs. One-way ANOVA analysis revealed no effect of sex or race on VT. There was 
no correlation between age and volume or volume ratio for any of the 10 ROIs. 
Discussion 
PET imaging using newly developed radiotracers that have superior specificity for the α4β2-nAChR 
and faster brain kinetics over previously used radioligands111 may further our understanding of 
changes in cholinergic activity over the course of cognitive decline112. Here we present the first 
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human neuroimaging data using PET and 18F-XTRA, a radiotracer with promising physical97 and in 
vivo96 characteristics. 
 
18F-XTRA readily accessed the brain in 17 healthy participants, all of whom underwent PET for 90 or 
180 min. The highest uptake was in the thalamus, with relatively lower uptake in the striatum, 
hippocampus, and cortex and lowest uptake in the corpus callosum, consistent with direct 
assessment in postmortem tissue87. After exclusion of thalamic data from 1 individual in whom 
thalamic activity peaked toward the end of the 90-min scan, VT values were well estimated using the 
2TCM and 90-min acquisition, especially in extrathalamic regions. The 2TCM was favored over the 
1TCM by goodness of fit and Akaike information criterion. The 2TCM VT and K1 values were well 
identified (COV < 5%) in all extrathalamic regions and reasonably identified (COV = 5.4%) in the 
thalamus. K1 was also high (K1 > 0.48 mL cm−3 min−1 in all cortical and subcortical ROIs; K1 = 0.30 
mL cm−3 min−1 in corpus callosum), consistent with high radiotracer delivery. Overall, the observed 
high uptake into the brain, fast pharmacokinetics, and ability to estimate VT in extrathalamic regions 
with a 90-min scan supports further use of 18F-XTRA in clinical research. 
 
This initial evaluation of 18F-XTRA in healthy humans revealed a negative correlation between age 
and VT in the hippocampus. Since amyloid plaque may negatively influence expression of this 
receptor102, all elderly (≥50-y-old) participants were evaluated for APOE ε4 carrier status. Those 
older individuals lacked even 1 APOE ε4 allele and were therefore at relatively low risk for having 
high amyloid burden. There was also no correlation between age and hippocampal volume or 
volume ratio among these participants. Together, our results suggest that 18F-XTRA PET may be 
sufficiently sensitive to measure the hypothesized loss of α4β2-nAChR availability over aging in 
extrathalamic regions89–91, particularly the hippocampus, in which reduced expression of the β2 
subunit may account for the lower α4β2-nAChR binding in the elderly113. This aging effect was not 





18F-XTRA VT estimates were higher in most human extrathalamic brain regions than VT values from 
bolus injection of other recently developed radiotracers with fast pharmacokinetics, such as (−)-18F-
flubatine107,115 and 18F-AZAN116. Since VT represents the sum of both specific binding and 
nondisplaceable uptake81, we note the limitation that a displacement study, such as using nicotine, is 
needed to compare specific binding patterns between recently developed radiotracers. Limited 
blocking studies in baboons using 18F-XTRA PET after subcutaneous administration of cytisine, a 
selective partial agonist at the α4β2-nAChR, support the specificity of this radiotracer for its target96. 
Although 18F-XTRA also has high affinity for the α6 nicotinic receptor subunit97, central receptors 
containing the α6 subunit are relatively limited in distribution (retina, catecholaminergic nuclei) 
compared with the widespread, higher density of the α4β2-nAChR117. We also note that thalamic 
data from 1 individual among the 17 participants did not peak until close to the end of the 90-min 
scan, rather than peaking at approximately 70 min. Since we saw a similar, late peak in thalamic 
data in 1 of 5 baboons96, a conservative approach for studying the α4β2-nAChR in the human 
thalamus may use longer 18F-XTRA scan duration (180 min) or use an alternative radiotracer that 
has not shown outlier thalamic pharmacokinetics, such as 18F-AZAN116. 
Conclusion 
18F-XTRA is a promising new radiotracer for measuring the human cerebral α4β2-nAChR in vivo. 
Analysis by the 2TCM using 18F-XTRA data from 90-min scan duration is sufficient to estimate VT in 
extrathalamic ROIs, such as the cerebral cortex, hippocampus, and striatum. 18F-XTRA PET is also 
a promising tool for further study of the effect of aging on the availability of the α4β2-nAChR, 





Figure 4-1. Time–activity curves from 18F-XTRA imaging in a representative subject who underwent 180 min of continuous 
emission imaging. 
(A) Radioactivity curves in total plasma and in the portion of unmetabolized 18F-XTRA parent are shown with activity shown 
as percentages of injected dose per mL plasma normalized to body weight in grams (SUV%). (B) Radioactivity curves 
spanning 180 min in 10 ROIs are shown. Time–activity curves are shown as percentages of injected dose per cm3 tissue 
normalized to body weight in grams (SUV%). (C) The 2TCM showed better fit to observed tissue time–activity curves than 
the 1TCM in all ROIs. Observed activity (data in shapes) and model curves (solid curve, 2TCM; dotted curve, 1TCM) over 





Figure 4-2. Comparison between 18F-XTRA regional VT values using 2TCM and Logan graphical analysis using 90-min data 
from 17 healthy individuals. 
After exclusion of outlier thalamic data from 1 individual, regional VT values from 2TCM were highly correlated with those 
from the Logan method (Spearman rho = 0.986, P = 0.000). Results from secondary regression analysis are also shown. VT 





Figure 4-3. Assessment of relative stability in 18F-XTRA regional VT values from 180 min of data compared with values 
produced from truncated (by 5-min intervals down to 90 min) scan duration. 
Data from 7 healthy individuals who underwent 180-min emission scans were included. VT estimates are in units of mL cm−3. 
Percentage of absolute difference between VT values from 180 min of data and VT values from shortened scan duration are 





Figure 4-4. Parametric images of VT of 18F-XTRA, estimated using Logan graphical analysis with metabolite-corrected 
arterial input function and 90-min data from 1 representative healthy participant. 
Transaxial views of PET/MR images demonstrate high VT values in thalamus and lower VT values in other cortical and 




Table 4-1. Clinical and Demographic Characteristics of 17 Healthy Human Participants 
Characteristic Mean or number 
Mean age ± SD (y) 56.7 ± 19.6 
Sex (male/female) 11/6 
Race (Caucasian/African American/Asian) 9/7/1 




Table 4-2. Kinetic Parameters and Total Distribution Volume (VT) Values Estimated with 2TCM, Along with VT Values 
Estimated Using 1TCM and Logan Analysis for 18F-XTRA PET Imaging in Humans (n = 17) 
  2TCM     
ROI  
K1 














0.61 ± 0.10 
(2.9 ± 1.6) 
0.15 ± 0.11 
(22.2 ± 12.0) 
13.0 ± 8.1 
(21.8 ± 11.2) 
66.6 ± 17.4 
(5.4 ± 9.7) 
 
57.7 ± 13.4 
(3.5 ± 1.1) 
 
64.1 ± 18.4 
(2.6 ± 1.0) 
Striatum  
0.52 ± 0.09 
(1.8 ± 1.0) 
0.07 ± 0.02 
(9.6 ± 5.9) 
1.29 ± 0.50 
(13.6 ± 7.9) 
17.3 ± 3.4 
(4.6 ± 4.0) 
 
14.5 ± 1.9 
(2.6 ± 0.5) 
 
16.7 ± 2.9 




0.48 ± 0.07 
(2.5 ± 1.3) 
0.12 ± 0.05 
(11.8 ± 5.9) 
2.92 ± 1.22 
(12.1 ± 5.9) 
15.6 ± 1.9 
(3.6 ± 2.6) 
 
12.9 ± 1.5 
(3.8 ± 0.6) 
 
15.6 ± 2.0 




0.52 ± 0.07 
(1.6 ± 0.9) 
0.08 ± 0.03 
(10.4 ± 5.2) 
1.80 ± 0.53 
(13.3 ± 6.5) 
17.6 ± 3.0 
(2.3 ± 2.9) 
 
15.8 ± 2.3 
(2.4 ± 0.5) 
 
17.7 ± 3.1 




0.49 ± 0.08 
(1.8 ± 1.3) 
0.10 ± 0.05 
(10.1 ± 7.6) 
1.66 ± 1.01 
(12.6 ± 8.1) 
13.7 ± 2.2 
(2.4 ± 2.5) 
 
12.2 ± 1.9 
(2.6 ± 0.5) 
 
13.6 ± 2.3 




0.56 ± 0.09 
(1.7 ± 1.3) 
0.11 ± 0.04 
(7.7 ± 6.0) 
1.60 ± 0.80 
(9.4 ± 6.4) 
13.4 ± 2.1 
(2.5 ± 2.3) 
 
11.5 ± 1.9 
3.2 ± 0.6) 
 
13.2 ± 2.3 




0.59 ± 0.09 
(2.5 ± 1.6) 
0.13 ± 0.08 
(12.5 ± 7.8) 
2.35 ± 1.56 
(13.9 ± 7.1) 
15.7 ± 2.9 
(2.4 ± 2.3) 
 
14.0 ± 2.4 
(3.0 ± 0.5) 
 
15.8 ± 3.1 




0.56 ± 0.08 
(2.1 ± 1.5) 
0.12 ± 0.07 
(10.5 ± 7.9) 
2.30 ± 1.65 
(12.0 ± 7.2) 
15.8 ± 3.1 
(2.5 ± 2.4) 
 
13.8 ± 2.5 
(2.9 ± 0.5) 
 
15.6 ± 3.3 




0.57 ± 0.09 
(1.8 ± 1.2) 
0.11 ± 0.05 
(9.1 ± 6.2) 
1.94 ± 1.07 
(10.9 ± 6.1) 
15.1 ± 2.7 
(2.5 ± 2.4) 
 
13.1 ± 2.3 
(3.1 ± 0.6) 
 
15.0 ± 3.0 




0.30 ± 0.06 
(4.1 ± 1.8) 
0.12 ± 0.06 
(21.0 ± 8.5) 
3.15 ± 2.12 
(23.5 ± 9.9) 
10.1 ± 1.7 
(4.7 ± 4.5) 
 
8.8 ± 1.5 
(3.4 ± 0.7) 
 
9.8 ± 1.6 
(3.5 ± 2.0) 
* One individual had poor fit for data from thalamus using all models tested, and these outlier data from thalamus of this 
individual were excluded. Regional VT values were generated using metabolite-corrected arterial input function and 90-min 
dynamic data. 





Supplemental Figure 4-1. [18F]XTRA parent fraction (%) plotted over the 90 minute scan duration. 
Mean data (black diamonds) are plotted from the 17 healthy individuals at each measured time point, with error bars 





Supplemental Figure 4-2. Scatter plot of [18F]XTRA total distribution volume values (VT) in the hippocampus from 17 
healthy individuals plotted against age. 
Regional VT was estimated using metabolite-corrected arterial input function and Logan analysis (t* = 45 minutes) from 90 
minute [18F]XTRA data. Using Spearman’s rank-order correlation analysis, there was an inverse correlation between age 




Supplemental Table 4-1. Regional volume measurements within the study population of 17 healthy individuals. 
ROI ROI Volume* ROI Volume 
Ratio* 
Thalamus 15.5 ± 1.8 0.010 ± 0.001 
Striatum 18.3 ± 2.4 0.012 ± 0.002 
Hippocampus 8.3 ± 0.8 0.005 ± 0.001 
Cerebellar CTX 101 ± 10.5 0.066 ± 0.006 
Temporal CTX 89.9 ± 9.1 0.058 ± 0.005 
Occipital CTX 44.2 ± 5.9 0.029 ± 0.003 
Cingulate CTX 19.6 ± 2.9 0.013 ± 0.002 
Frontal CTX 165 ± 15.7 0.107 ± 0.006 
Parietal CTX 106 ± 10.4 0.068 ± 0.004 
Corpus Callosum 3.4 ± 0.3 0.002 ± 0.000 
Total ICV 1544 ± 126.7 N/A 
*Presented as Mean ± Standard Deviation. ROI volume is in units of cm3. Volume relative to total intracranial volume (ICV) is 




Supplemental Table 4-2. Akaike's Information Criterion values from compartmental modeling applied to 90 minutes 
dynamic [18F]XTRA PET imaging data in humans (N=17). 
ROI  1TCM*  2TCM* 
Thalamus  -11.4 ± 22.3 
 
 -58.1 ± 28.3 
 
Striatum  38.4 ± 15.9 
 
 -26.0 ± 30.6 
 
Hippocampus  58.4 ± 11.3 
 
 -14.0 ± 25.9 
 
Cerebellar CTX  32.5 ± 16.1 
 
 -40.6 ± 35.1 
 
Temporal CTX  42.4 ± 14.3 
 
 -32.6 ± 37.1 
 
Occipital CTX  56.6 ± 14.6 
 
 -29.3 ± 37.5 
 
Cingulate CTX  50.1 ± 12.6 
 
 -18.2 ± 30.3 
 
Frontal CTX  49.4 ± 13.8 
 
 -26.9 ± 32.7 
 
Parietal CTX  52.8 ± 14.8 
 




 48.6 ± 15.3 
 
 10.5 ± 20.9 
 
*Presented as Mean ± Standard Deviation. Region of Interest, ROI; One-tissue compartment model, 1TCM; Two-tissue 




Supplemental Table 4-3. The absolute percent difference between [18F]XTRA regional total distribution volume (VT) values 
calculated from 90 minutes and from 180 minutes of dynamic data from the same individuals (N = 7). 
ROI Difference between VT 
estimates* 
Thalamus 4.93 ± 6.29% 
Striatum 3.99 ± 4.12% 
Hippocampus 4.59 ± 4.42% 
Cerebellar CTX 3.07 ± 2.96% 
Temporal CTX 3.53 ± 3.09% 
Occipital CTX 3.95 ± 3.15% 
Cingulate CTX 3.43 ± 3.21% 
Frontal CTX 3.46 ± 2.78% 
Parietal CTX 4.13 ± 3.04% 
Corpus Callosum 4.38 ± 5.43% 
*Presented as Mean ± Standard Deviation. Regional VT values in units of mL cm-3 were generated using Logan analysis with 




Chapter 5: Examining brain inflammatory processes 
through kinetic modeling of radiotracers in human clinical 
studies: A study of [18F]ASEM in healthy aging 
Summary: 
The focus of this chapter is on the use of [18F]ASEM to study the distribution of the alpha7 nicotinic 
acetylcholine receptor (α7-nAChR) in healthy aging. In this study, we utilized positron emission 
tomography to study the distribution of [18F]ASEM in 25 healthy adult volunteers. Using PMOD, we 
were able to use the time activity curves generated for the 9 regions of interest (ROIs) to 
characterize the binding of [18F]ASEM to α7-nAChR using a one-tissue compartment model and 
Logan graphical analysis. We used total distribution volumes (VT) generated from Logan graphical 
analysis to test the relationship between age and VT in the ROIs. Additionally, in a subset of healthy 
volunteers age 50 and older, we used Logan graphical analysis VT to test the relationship between 




The distribution of the alpha7 nicotinic acetylcholine receptor in healthy 
aging: An in vivo positron emission tomography study with [18F]ASEM 
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Altered function of the alpha7 nicotinic acetylcholine receptor (α7-nAChR) is implicated in several 
neuropsychiatric diseases. Nevertheless, studies of the human cerebral α7-nAChR even in healthy 
aging are limited in number and to postmortem tissue. 
Methods 
The distribution of the cerebral α7-nAChR was estimated in nine brain regions in 25 healthy 
volunteers (ages 21–86 years; median 57 years, interquartile range 52 years) using [18F]ASEM with 
positron emission tomography (PET) imaging. Regional total distribution volume (VT) measurements 
were calculated using the Logan method from each subject's 90 min dynamic PET data and their 
metabolite-corrected plasma input function. Spearman's rank or Pearson's correlation analysis was 
used depending on the normality of the data. Correlation between age and regional 1) volume 
relative to intracranial volume (volume ratio) and 2) [18F]ASEM VT was tested. Correlation between 
regional volume ratio and [18F]ASEM VT was also evaluated. Finally, the relationship between 
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[18F]ASEM VT and neuropsychological measures was investigated in a subpopulation of 15 elderly 
healthy participants (those 50 years of age and older). Bonferroni correction for multiple 
comparisons was applied to statistical analyses. 
Results 
A negative correlation between tissue volume ratio and age was observed in six of the nine brain 
regions including striatum and five cortical (temporal, occipital, cingulate, frontal, or parietal) regions. 
A positive correlation between [18F]ASEM VT and age was observed in all nine brain regions of 
interest (ROIs). There was no correlation between [18F]ASEM VT and volume ratio in any ROI after 
controlling for age. Regional [18F]ASEM VT and neuropsychological performance on each of eight 
representative subtests were not correlated among the well-performing subpopulation of elderly 
healthy participants. 
Conclusions 
Our results suggest an increase in cerebral α7-nAChR distribution over the course of healthy aging 
that should be tested in future longitudinal studies. The preservation of the α7-nAChR in the aging 
human brain supports the development of therapeutic agents that target this receptor for use in the 
elderly. Further study of the relationship between α7-nAChR availability and cognitive impairment 
over aging is needed. 
 
Introduction 
The alpha7 nicotinic acetylcholine receptor (α7-nAChR) is expressed on neurons and has functional 
roles in synaptic transmission, neurotransmitter release, intracellular signaling, and synaptic 
plasticity that collectively mediate cognitive function118. Human post-mortem studies support altered 
distribution of the cerebral α7-nAChR in neuropsychiatric illness, including studies of 
schizophrenia119,120 and Alzheimer's disease121. Since there is evidence implicating the α7-nAChR in 
various disease processes, the utility of new therapies targeting the α7-nAChR is being evaluated in 
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patient populations with cognitive or affective symptoms122–128. Nevertheless, our understanding of 
the availability of the α7-nAChR even in healthy aging is incomplete since studies of human brain 
tissue that focus on this receptor subtype are limited in number and to a narrow selection of 
examined regions129. New techniques designed to image the α7-nAChR in vivo promise to help 
elucidate changes in the distribution of the cerebral α7-nAChR in healthy aging and disease 130,131. 
 
A radioligand for imaging the α7-nAChR, [18F]ASEM, was developed by our group130 and has shown 
promising pharmacokinetic characteristics in early human neuroimaging studies using positron 
emission tomography (PET)132,133. [18F]ASEM enters the brain rapidly and within 15–30 min after 
intravenous (IV) bolus radiotracer injection the standardized uptake values peak around 3.0–4.5 
before gradual decline in all regions. Two recent studies using this radiotracer in human 
neuroimaging support the use of graphical analysis (plasma reference graphical analysis [PRGA], 
multilinear analysis method [MA1]) to derive the primary binding outcome, regional total distribution 
volume (VT), using data from at least 90 min of dynamic imaging132,133. The test-retest variability of 
[18F]ASEM human PET data was 10.8 ± 5.1% and 11.7 ± 9.8% across the brain regions tested in 
these two independent studies of healthy controls. 
 
Here, we aimed to use [18F]ASEM PET-based neuroimaging in a new group of healthy individuals to 
investigate the availability of the α7-nAChR within the context of healthy aging. We focused on the 
binding of [18F]ASEM in nine regions, including those suspected to have lower (thalamus, frontal 
cortex) or unchanged (hippocampus, striatum) availability of the α7-nAChR in the aged brain based 
on limited results using α-bungarotoxin or assay of mRNA in human postmortem tissue134–137. Since 
decline in cholinergic signaling is seen across the lifespan and may be linked to compensatory re-
distribution of the α7-nAChR or to cognitive deficits in elderly individuals, we also assessed the 
relationship between regional [18F]ASEM VT and 1. Regional brain volume as well as 2. Cognitive 
performance, the latter among the subset of participants who were 50 years of age or older. 
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Materials and Methods 
Human Subjects 
A Johns Hopkins Institutional Review Board approved this study and all participants provided written 
informed consent. Use of [18F]ASEM is conducted under a FDA exploratory IND. Healthy adult (over 
age 18 years) participants were recruited through local advertising. Each subject completed a careful 
clinical interview and physical assessment with screening blood work, electrocardiogram (EKG), and 
urine toxicology. Eligibility criteria included stable health, with no clinical abnormality on a screening 
health assessment and the structural magnetic resonance imaging (MRI). Exclusion criteria included 
nicotine use, any current or past psychiatric or neurological illness (including history of head injury 
with loss of consciousness), history of recreational substance abuse including marijuana (assessed 
by self-report and urine toxicology), prescribed medication known to affect acetylcholine signaling 
(including but not limited to anticholinergic and certain 5HT3 anti-emetic medications), any current 
psychotropic medication use, contraindication to MRI (i.e. implanted metal, claustrophobia), or 
contraindication to PET imaging with arterial line placement (i.e. clotting factor deficiency, 
pregnancy/breast feeding, prior radiation exposure). Participants completed the Mini Mental State 
Examination (MMSE)138 to assess global cognitive performance. Older participants (age 50 years 
and older) in this study were also assessed using a battery of neuropsychological tests. We chose to 
focus on eight representative subtests from this comprehensive battery to characterize performance 
of these elderly participants across the neurocognitive domains of attention [Digit Span Forwards 
from Wechsler Adult Intelligence Scale Third Edition139; Delis-Kaplan Executive Functioning System 
(DKEFS)140 Number Sequencing Time], working memory [DKEFS Number-Letter Sequencing Time], 
language [DKEFS Category Fluency], executive function [DKEFS Letter Fluency], visuospatial ability 
[Clock Drawing Test141], and verbal learning and memory [California Verbal Learning Test (CVLT)142 
Total Recall from Trials 1–5; CVLT Long Delay Free Recall]. 
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DNA Extraction and Genotyping 
A blood sample was collected from those participants age 50 years and older for DNA 
extraction (PureGene® Blood Core Kit C, Qiagen, Valencia, CA) according to manufacturer's 
instructions. Genotyping of the two single nucleotide polymorphisms (SNPs) that determine the three 
possible alleles of the gene for apolipoprotein E, APOE, was completed using TaqMan genotyping 
assays (rs429358: cat# 4351379, rs7412: cat# 4351379, Applied Biosytems, Foster City, CA) on a 
CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad, Hercules, CA). Analyses of the six 
different APOE genotypes: ε2/ε2, ε3/ε3, ε4/ε4, ε2/ε3, ε2/ε4, and ε3/ε4 were completed using the CFX 
Manager™ Software (Bio-Rad, Hercules, CA). Individuals with at least one ε4 allele were 
categorized as APOE ε4 carriers. 
In Vivo Brain Imaging 
Radiotracer synthesis and PET acquisition 
[18F]ASEM was synthesized as previously described by one-step microwave radiosynthesis via the 
corresponding nitro-precursor143, and met all U.S. Pharmacopeia Convention Chapter <823> 
acceptance testing criteria. Radiochemical purity at end of synthesis was >98% with high specific 
radioactivity (2306 ± 2164 GBq/μmol) at the time of IV bolus radiotracer injection and onset of the 
dynamic listmode PET acquisition. The average injected dose of radioactivity was 510.1 ± 41.0 MBq 
with injected mass of 0.19 ± 0.17 μg. 
PET acquisition 
A thermoplastic mask was fitted to each subject's face for immobilization and positioning of the head 
during scanning. PET continuous listmode data were acquired using a High Resolution Research 
Tomograph scanner (HRRT, Siemens Healthcare, Knoxville,TN), an LSO-based, dedicated brain 
PET scanner with <2.5 mm reconstructed image resolution104. Four participants (two females with 
ages 26 and 82 years, and two males with ages 25 and 67 years) underwent data collection for 120 
min. This longer scan time was used to validate further the use of a 90 min emission scan. Ninety 
min of continuous listmode data were acquired from each subsequent participant. One hundred and 
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twenty min of listmode data were binned into 36 frames (four 15 s, four 30 s, three 1 min, two 2 min, 
five 4 min, and eighteen 5 min frames). Ninety min of listmode data were binned using the same 
frame protocol with six less 5 min frames (total of 30 frames). The data were then reconstructed 
using the iterative ordinary-Poisson ordered-subset expectation-maximization algorithm (6 iteration 
and 16 subsets, 2 mm post-smoothing), with correction for radioactive decay, dead time, attenuation, 
scatter and randoms80. The attenuation maps were generated from 6 min transmission scans 
performed with a 137Cs point source prior to the emission scans. The reconstructed image volume 
spanned 31 cm × 31 cm transaxially and 25 cm axially. The image matrix consisted of 256 × 256 x 
207 voxels and a voxel size of 1.22 × 1.22 × 1.22 mm3. 
Plasma sampling 
All participants underwent radial arterial line placement prior to radiotracer injection. Measurement of 
the arterial plasma input function was conducted through collection of 35–50 blood samples (1 mL) 
that were obtained at the following intervals after bolus radiotracer injection (p.i.): as fast as possible 
for the initial 1.5 min p.i., every 30 s between 1.5 and 3 min p.i., once at 5 min p.i., and then every 5 
min for the duration of the 90 or 120 min continuous emission scan. The fraction of parent 
radioligand in plasma was determined by high performance liquid chromatography (HPLC) analysis 
from collection of 3–6 mL blood samples before radiotracer injection (background) and at 5, 10, 20, 
30, 45, 60, 75, and 90 min p.i. Scans lasting 120 min had additional blood sampling for metabolite 
measurements at 105 and 120 min p.i. 
 
Briefly, the modified column-switching HPLC method105 used an Agilent Technologies system 
containing a 1 260 Infinity quaternary pump, a 1 260 Infinity column compartment module, a 1260 
Infinity UV detector, and a Bioscan radiation detector that was controlled by OpenLab CDS 
EZChrom (A.01.04) software. Each plasma sample (1–2 mL) was loaded onto a 4 mL Rheodyne 
injector loop and was initially directed to the capture column (packed with Phenomenex Strata-X 
33 μm polymeric reversed phase sorbent) and detectors using 1% acetonitrile and 99% water mobile 
phase at 2 mL/min to detect polar metabolites. After 2 min of elution, an analytical mobile phase 
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composed of 40% acetonitrile and 60% aqueous triethylamine at a concentration of 0.1 M and 
pH = 7.1 (adjusted with phosphoric acid) was applied to elute trapped non-polar metabolites and 
parent radiotracer onto an analytical column (Waters, reverse phase XBridge BEH C18 5 μM 
4.6 × 250 mm) at 2 mL/min. 
Measurement of Plasma Free Fraction (fP) 
Plasma Free Fraction (fP) was measured using rapid equilibrium dialysis (RED). Plasma samples 
were isolated by centrifugation from one blood sample obtained from each participant before 
radiotracer injection. A 300 μL sample of plasma was spiked with 3 μCi of [18F]ASEM and added into 
the sample chamber of Single-Use RED Plate with Inserts (Thermo Scientific, Rockford, IL, USA) 
with an 8 K molecular-weight cutoff. 500 μL of PBS was added to the buffer chamber and the plate 
was incubated on an Incubating Microplate Shaker (Fisher Scientific, Waltham, MA, USA) at 37 °C 
for 4 h. 100 μL of plasma and 100 μL of PBS were transferred to a clean tube. All samples were 
measured in triplicate. The radioactivity was measured using a 2 480 WIZARD2 Gamma Counter 
(Perkin Elmer, Waltham, MA, USA) to obtain the radioactivity in the plasma (CP) and buffer (CU). The 
free, unbound fraction (fP) was calculated as: fP = CU/CP x 100 (%). 
MRI acquisition 
MR structural T1-weighted imaging was acquired on a Siemens MAGNETOM Prisma or on a 
Siemens MAGNETOM Trio 3 Tesla scanner (Malvern, PA, USA) with a Trio head matrix 12-channel 
head coil or Prisma head/neck 20-channel head coil, to obtain a 0.8 × 0.8 × 0.8 mm3 3-dimensional 
(3D) Magnetization-Prepared Rapid Gradient-Echo (MP-RAGE) sequence. 
Data Analysis and Statistics 
Image processing 
The software package PMOD (v3.7, PMOD Technologies Ltd, Zurich, Switzerland) was used in the 
initial PET image processing and kinetic analysis. Inter-frame motion correction was applied post-
reconstruction using the motion correction function in PMOD. First, a static reference frame was 
generated by averaging the frames corresponding to the 30–60 min p.i. Second, the motion 
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correction was accomplished by rigid matching of the dynamic data to the reference image frame by 
frame. PET-MRI co-registration was completed as previously described144. Cortical reconstruction 
and volumetric segmentation of T1-weighted MR images were performed with the FreeSurfer image 
analysis suite (http://surfer.nmr.mgh.harvard.edu/). Nine regions of interest (ROIs) were selected for 
this study: thalamus, striatum, hippocampus, cerebellar cortex, temporal cortex, occipital 
cortex, cingulate cortex, frontal cortex and parietal cortex. Total intracranial volume (ICV) was also 
defined using FreeSurfer, for use in analyses exploring the correlation between age and ROI volume 
normalized to ICV, herein referred to as regional volume ratio. Correlation between regional volume 
ratio and binding of [18F]ASEM was also tested. PET time-activity curves (TACs) were generated for 
all subjects using the ROI definitions. 
Calculation of regional total distribution volume (VT) 
The primary PET-based regional binding outcome was total distribution volume, VT, defined as the 
ratio of the concentration of the radioligand in brain tissue to that in plasma at equilibrium81. The 
kinetics of [18F]ASEM can be modeled using graphical analysis132,133. Here, VT within each ROI was 
estimated using Logan graphical analysis82 with fixed t* = 45 min, which was chosen for its 
computational simplicity and independence from assumed compartmental characteristics of the data. 
Regional VT values generated using Logan analysis with metabolite-corrected arterial input function 
from 120 min dynamic scans among four participants were compared to VT values obtained with 
data shortening down to 90 min in order to validate further the proposed use of 90 min of continuous 
PET data. Since the 1TCM yields equal133 or improved132 model suitability compared to two-tissue 
compartmental modeling (2TCM), regional VT values from the Logan method were compared to 
those generated using one-tissue compartmental modeling (1TCM) using 90 min data for all 25 
individuals. Compartmental modeling used a fixed blood volume of 5%. Plasma free fraction (fP) was 
measured for 18 of the 25 subjects, with mean ± standard deviation (SD) = 0.05 ± 0.01. Regional 





Statistical analyses were performed using SPSS Statistics (Version 23.0, IBM Corp., Armonk, NY, 
USA). Data were checked for outliers, and descriptive statistics were obtained. Normality of the data 
was assessed using the Shapiro-Wilk test. The relationships between 1) regional [18F]ASEM 
VT values and age (as well as other descriptive variables) and 2) ROI volume ratios and age were 
tested using Spearman's rank-order correlation analysis since age was found to not be normally 
distributed across the study population. These analyses were repeated for the secondary binding 
outcome, regional VT/fP. 
 
The threshold for significance for all statistical tests involving regional VT and regional volume 
measures accounted for the nine ROIs using a Bonferroni adjusted alpha level of 0.0056 per test 
(approximately = 0.05/9). The threshold for significance in all statistical tests involving the eight 
representative neuropsychological tests was set as P < 0.0063 (approximately = 0.05/8). Data were 
expressed as mean ± SD unless otherwise noted. 
Results 
Human Subject Participation 
Twenty-five healthy participants, ranging in ages from 21 to 86 (median 57; interquartile range 52) 
years participated in [18F]ASEM PET neuroimaging (Table 5-1). Participants had 13–23 years of 
education. Four of the 25 participants (ages 27.75 ± 5.12 years, range 21–33 years) did not 
complete the MMSE on the morning of the PET due to late addition of this test variable. MMSE 
scores among 21 participants ranged from 27 to 30 out of 30 possible points (29.38 ± 0.92). There 
was no correlation between MMSE and age. All 15 older (defined as age 50 years or older) 
participants completed the neuropsychological assessment (Table 5-2). Increasing age was not 
associated with poorer cognitive performance on any of the eight representative tests (Supplemental 




ROI volumes as well as ICV are presented in Table 5-3. Spearman's rank-order correlation analyses 
revealed negative correlation between regional volume ratio and age in striatum, temporal cortex, 
occipital cortex, cingulate cortex, frontal cortex, and parietal cortex (Table 5-3,Figure 5-1). 
[18F]ASEM PET imaging 
Regional VT values generated using Logan analysis with metabolite-corrected arterial input function 
from 90 min continuous scans were within 5% of the VT values obtained using 120 min of continuous 
[18F]ASEM data (Supplemental Figure 5-1,Supplemental Table 5-2). Using 90 min data, regional VT 
values from the Logan method were comparable to VT values estimated using the 1TCM (Table 5-4). 
Furthermore, regional VT values from the Logan method highly correlated with those from using the 
1TCM (Spearman's rho = 0.945, P < 0.001) (Supplemental Figure 5-2). 
 
Spearman's rank-order correlation analyses revealed no correlation between K1 and age in all nine 
regions of interest. Regional VT values generated using Logan analysis with metabolite-corrected 
arterial input function from 90 min scan duration were used in all other correlation analyses 
hereafter, unless otherwise stated. 
 
Spearman's rank-order correlation analyses revealed positive correlation between [18F]ASEM 
regional VT values and age in all nine ROIs (Table 5-4,Figure 5-2). Secondary analyses revealed 
positive correlation between VT/fP and age in striatum and parietal cortex (Supplemental Table 5-3), 
and fP did not correlate with age. There was no correlation between [18F]ASEM VT in any of the ROIs 
and sex, race, body mass index, years of education, or MMSE score. There was no correlation 
between [18F]ASEM VT and volume ratio in any ROI after controlling for age (Supplemental Table 5-
4). Finally, post hoc analyses revealed positive correlation between [18F]ASEM VT estimates from the 




Among the 15 individuals age 50 years and older, there was no significant correlation found between 
[18F]ASEM VT in any ROI and performance on any of the eight representative cognitive measures 
after Bonferroni correction. However, without correction for multiplicity, a negative correlation (P < 
0.05) between the DKEFS Number Sequencing Time, a test of attention, and [18F]ASEM VT in 
occipital cortex (rho = −0.534, P = 0.040) was observed, reflecting a trend of poorer performance in 
those with lower binding in this region (Supplemental Figure 5-3). 
Discussion 
The relationship between cognitive decline in healthy aging and cholinergic dysfunction is likely 
related to complex underlying factors that may include loss of cholinergic projections, deficits in 
acetylcholine signaling with secondary effects on other neurotransmitter release, or changed 
distribution of nicotinic receptor subtypes113. Converging evidence from pharmacological studies and 
animal models suggests the important role of the α7-nAChR in cognitive function145. The ability to 
estimate the distribution of the α7-nAChR in vivo using [18F]ASEM with PET imaging may help 
elucidate the hypothesized link between cerebral α7-nAChR availability and cognitive decline, even 
over the healthy human lifespan130,131. 
 
In the present study, we assessed the relationship between the availability of the α7-nAChR and 
healthy aging. Using non-parametric (Spearman's rank) correlation analysis, a positive correlation 
between [18F]ASEM VT and age was observed in all nine ROIs, which included cortical and 
subcortical regions. Consistent with previously reported regional decreases in brain volume over 
normal aging 146–148, we observed a negative correlation between the tissue volume ratio and age in 
several of these ROIs, namely striatum, temporal cortex, occipital cortex,  cingulate cortex, frontal 
cortex, and parietal cortex. There was no correlation between [18F]ASEM VT and volume ratio in any 
ROI after controlling for age. While this study is limited by small sample size, our results support the 
promising utility of [18F]ASEM neuroimaging to examine the relationship between the distribution of 
the α7-nAChR, onset of regional brain atrophy, and related clinical changes over the course of 
102 
 
healthy aging. Furthermore, these results suggest a link between higher cerebral availability of the 
α7-nAChR with aging that may prove important to our understanding of cholinergic signaling over the 
lifespan. Specifically, these results suggest an increase in the cerebral α7-nAChR, perhaps as a 
compensatory response to lower acetylcholine signaling, over the course of healthy aging that 
should be tested in animal models and future longitudinal studies. The preservation of the α7-nAChR 
over normal aging supports the development of therapeutic agents that target this receptor for 
treatment of cognitive dysfunction in the elderly. 
 
This study benefits from several methodological strengths including a larger sample size of 
[18F]ASEM neuroimaging data from healthy individuals compared to two other recent studies132,133. 
[18F]ASEM neuroimaging data from this new group of 25 healthy individuals spanning ages 21–86 
years showed that use of the Logan graphical method with metabolite-corrected arterial input 
function, like other methods of graphical analysis132,133, yields regional VT estimates that are similar 
to those from the preferred compartmental tissue model, the 1TCM132, using 90 min of continuous 
dynamic emission data. One hundred and twenty min of emission data were acquired from four (two 
young and two elderly) of our 25 healthy participants and data shortening showed that VT estimates 
from a 90 min scan duration were within 5% of the values estimated from a 120 min scan duration 
for all ROIs. The methodological design also included careful assessment of neuropsychological 
performance in those individuals who were 50 years old or older in order to probe the relationship 
between distribution of [18F]ASEM binding and cognitive performance in late aging. This small 
subpopulation of 15 elderly controls showed no correlation between performance on the selected 
neuropsychological subtests and increasing age. Similarly, there were no significant correlations 
found between regional [18F]ASEM VT values and cognitive measures among this well-performing 
population of healthy participants. Nevertheless, the observed trend of a negative correlation 
between performance on the DKEFS Number Sequencing, a test of attention, and [18F]ASEM VT in 
occipital cortex should be tested further in larger studies of aging individuals with more varied 
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neuropsychological performance given the hypothesized key role of the α7-nAChR in modulating 
tasks of sustained attention149. 
 
There are some important methodological and biological factors that should be considered and 
further investigated in future [18F]ASEM PET imaging studies in aging and disease. First, we defined 
regional VT as our primary binding outcome. Since only free radioligand enters brain, we also 
measured fP, and calculated regional VT/fP as a secondary outcome measure. The values obtained 
for fP were 5 ± 1% and therefore very similar to those reported in six healthy participants (7.7 ± 1.3%) 
by Hillmer et al. However, the correlation between [18F]ASEM binding and age was only observed in 
striatum and parietal cortex using VT/fP as the binding outcome. Since fP is an independent 
measurement and may introduce further noise from plasma data, it is possible that [18F]ASEM lacks 
sensitivity to detect changes in VT/fP in all affected ROIs over aging, especially in the setting of small 
sample size. On the other hand, the limited number of postmortem studies to-date do not report 
evidence of higher availability of the α7-nAChR in elderly cases129. Since amyloid burden in the brain 
may also be associated with upregulated cerebral expression of the α7-nAChR150,151, the effect of 
this potential synergistic relationship should be examined in future in vivo or in vitro studies. Since 
there were only three individuals found to be APOE4 carriers in this population, we could not 
sufficiently test for this effect that could be a focus of future studies. Second, it is important to note 
that [18F]ASEM PET signal is only an indirect measure of the α7-nAChR in the living brain. Our 
results support further in vitro experiments of the α7-nAChR directly, in carefully selected 
postmortem tissue from individuals of all ages. 
Conclusions 
By demonstrating a positive correlation between [18F]ASEM binding and age in several brain regions 
of healthy individuals, we support future use of [18F]ASEM PET to examine the relationship between 
altered distribution of the α7-nAChR and clinical changes even over healthy aging. Since there is 
interest in targeting this receptor subtype to prevent or ameliorate cognitive deficits, human studies 
using [18F]ASEM in individuals with more robust impairment in cognitive performance will inform 
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further the lack of observed relationship between [18F]ASEM VT and performance on 
neuropsychological tests among elderly participants reported here. [18F]ASEM PET continues to 
demonstrate promise as a research tool for testing the relationship between altered availability of the 






Figure 5-1. Scatter plots of regional volume relative to total intracranial volume (volume ratio) plotted against age. 
Spearman's rank-order correlation analyses revealed negative correlation between regional volume ratio (unitless) and age 
in six (striatum, temporal cortex, occipital cortex, cingulate cortex, frontal cortex, and parietal cortex) of the nine regions of 
interest. Individual data points are shown for two representative regions including A) Striatum (rho = −0.605, P = 0.001) and 






Figure 5-2. Scatter plots of regional [18F]ASEM total distribution volume values (VT) plotted against age. 
Regional VT was estimated using metabolite-corrected arterial input function and Logan analysis (t* = 45 min) from 90 min 
[18F]ASEM data. Individual data points are shown for five representative regions including A) Striatum, B) Hippocampus, C) 
Cerebellar Cortex, D) Occipital Cortex and E) Parietal Cortex that were selected from the nine regions studied. Using 
Spearman's rank-order correlation analysis, all regions of interest in this study showed positive correlation between age and 
regional [18F]ASEM VT (P < 0.0056, which marks significance after applying Bonferroni correction for the nine regions 




Table 5-1. Clinical and demographic characteristics of 25 healthy human participants. 
Age (Years) 53.68 ± 24.59a 
Sex (Male/Female) 15/10 
Race (Caucasian/African-American) 18/7 
Body Mass Index 24.61 ± 3.32 
Education (Years) 16.96 ± 2.37 



















 aElderly healthy controls were defined as those participants age 50 years and older and all completed the 
neuropsychological assessment that included these eight representative tests. 
bScores presented as Mean (Standard Deviation) and range. California Verbal Learning Test, CVLT; Delis-Kaplan Executive 
Functioning System, DKEFS). 
  
Test Elderly Controlsa,b 
Digit Span Forwards139 7.2 (0.8) 
6-8 
DKEFS140 Number Sequencing Time (seconds) 36.6 (8.3) 
19-47 
DKEFS Number-Letter Sequencing Time (seconds) 97.7 (53.4) 
41.4-272.0 
DKEFS Category Fluency (Total number of words 
generated over 60 s) 
39.2 (7.3) 
29-57 
DKEFS Letter Fluency (Total number of words generated 
over 60 s) 
45.9 (11.1) 
31-70 
Clock Drawing Test141 9.3 (1.1) 
6-10 
CVLT142 Total number of words recalled - Sum of Trials 1-5 57.3 (10.5) 
41-76 
CVLT Long Delay Free Recall (Total number of words 





Table 5-3. Regional volume measurements within the study population of 25 healthy individuals and correlation between 











*P < 0.0056, which marks significance after applying Bonferroni correction for the nine regions tested. 
aPresented as Mean ± Standard Deviation. ROI volume is in units of cm3. Volume relative to total intracranial volume (ICV) is 
defined as volume ratio and is unitless. 
bSpearman’s rank correlation analysis was applied to each test of correlation between age and ROI volume ratio. Cortex, 
CTX; Region of Interest, ROI. 
  
ROI ROI Volumea ROI Volume Ratioa Rho (P value)b 
Thalamus 15.25 ± 1.96 0.010 ± 0.001 -0.438 (0.029) 
Striatum 18.05 ± 2.21 0.012 ± 0.002 -0.605 (0.001)* 
Hippocampus 8.48 ± 0.80 0.006 ± 0.001 -0.242 (0.243) 
Cerebellar CTX 104.83 ± 16.06 0.070 ± 0.009 -0.304 (0.140) 
Temporal CTX 92.37 ± 13.20 0.061 ± 0.007 -0.737 (<0.001)* 
Occipital CTX 42.98 ± 5.17 0.029 ± 0.003 -0.562 (0.003)* 
Cingulate CTX 19.44 ± 3.31 0.013 ± 0.001 -0.710 (<0.001)* 
Frontal CTX 165.69 ± 22.78 0.110 ± 0.009 -0.758 (<0.001)* 
Parietal CTX 103.95 ± 13.60 0.069 ± 0.005 -0.627 (0.001)* 
Total ICV 1509.79 ±169.20 N/A N/A 
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Table 5-4. K1 and Total Distribution Volume (VT) values estimated with the one-tissue compartmental model (1TCM), along 
with VT values and Correlation between age and regional VT estimated using Logan analysis (t* =45 minutes) for [18F]ASEM 
PET imaging in humans (N=25). 
*P < 0.0056, which marks significance after applying Bonferroni correction for the nine regions tested. 
aPresented as Mean ± Standard Deviation. Regional VT values were generated using metabolite-corrected arterial input 
function and 90 minute dynamic data. 
bSpearman’s rank correlation analysis was applied to each test of correlation between age and regional VT generated using 
Logan analysis. Cortex, CTX; Region of Interest, ROI. 
  
  1TCM   Logan  
ROI  K1a 
(mL cm-3 min-1) 
VTa 
(mL cm-3) 
 VTa  
(mL cm-3) 
Rho (P value)b 
Thalamus  0.36 ± 0.06 21.44 ± 4.68  22.78 ± 5.15 0.591 (0.002)* 
Striatum  0.35 ± 0.06 21.82 ± 5.96  22.60 ± 5.97 0.778 (< 0.001)* 
Hippocampus  0.27 ± 0.05 17.92 ± 3.38  19.77 ± 3.97 0.666 (< 0.001)* 
Cerebellar CTX  0.36 ± 0.06 16.17 ± 3.32  16.92 ± 3.44 0.718 (< 0.001)* 
Temporal CTX  0.30 ± 0.05 21.20 ± 3.68  22.30 ± 3.94 0.621 (0.001)* 
Occipital CTX  0.38 ± 0.07 20.34 ± 3.48  21.44 ± 3.66 0.652 (< 0.001)* 
Cingulate CTX  0.35 ± 0.06 20.78 ± 3.31  21.85 ± 3.51 0.610 (0.001)* 
Frontal CTX  0.36 ± 0.07 20.62 ± 4.16  21.45 ± 4.19 0.581 (0.002)* 




Supplemental Figure 5-1. Assessment of the relative stability in [18F]ASEM regional total distribution volume (VT) values 
calculated from 120 minutes of continuous data compared to values produced when the data is truncated by five minute 
intervals down to 90 minutes of continuous data. 
Data from four healthy individuals were included and VT estimates were in units of mL cm-3. The percent of the absolute 
difference between the VT values from 120 minutes of data and VT values from shortened scan duration are plotted for each 





Supplemental Figure 5-2. Comparison between [18F]ASEM regional total distribution volume (VT) values using 1TCM and 
Logan graphical analysis using 90 minute data from 25 healthy individuals. 
Regional VT values from the 1TCM were highly correlated with those from the Logan method (Spearman’s rho = 0.945, P < 





Supplemental Figure 5-3. Scatter plots of timed performance on the Delis-Kaplan Executive Functioning System (DKEFS) 
Number Sequencing Time test plotted against [18F]ASEM VT in the Occipital Cortex. 
Data was collected from 15 elderly (age 50 years and older), healthy individuals. Regional VT values were estimated using 
Logan graphical analysis from 90 minute [18F]ASEM data. Spearman’s rank correlation analysis was applied. The negative 
correlation between timed performance and VT (rho = -0.534, P = 0.040) did not survive statistical significance (P < 0.0063, 
which marks significance after applying Bonferroni correction for the eight representative neuropsychological tests). A line 




Supplemental Table 5-1. No significant correlation was observed between age and neuropsychological test performance 
among 15 healthy individuals who were age 50 years or older. 
 Neuropsychological Tests 
 Attention  WM  Lang  Exec  Visuospatial 
ability 
 Verbal Learning 
and Memory 
 DSF #  #-Let  Cat  LF  CDT  Recall Delay 
Age 0.121 0.103  0.077  0.166  -0.058  0.176  0.121 0.286 
aSpearman’s rank was used to test correlation between age and each neuropsychological test and the value for rho is 
presented. No significant correlation was observed even using a threshold of significance of P < 0.05, which does not 
account for multiple comparisons. Working Memory, WM; Language, Lang; Executive Function, Exec; Digit Span Forward, 
DSF; Delis-Kaplan Executive Functioning System (DKEFS) Number Sequencing Time, #;  DKEFS Number-Letter 
Sequencing Time, #-Let; DKEFS Category Fluency, Cat; DKEFS Letter Fluency, LF; Clock Drawing Test, CDT; CVLT Total 




Supplemental Table 5-2. The absolute percent difference between [18F]ASEM regional total distribution volume (VT) values 
calculated from 90 minutes of dynamic data and the values from 120 minutes of dynamic data from the same individuals (N 
= 4). 
ROI Difference between 
VT estimatesa 
Thalamus 3.41  ± 4.30% 
Striatum 3.98  ± 3.80% 
Hippocampus 4.65  ± 4.36% 
Cerebellar CTX 1.90  ± 1.98% 
Temporal  CTX 2.61  ± 3.60% 
Occipital  CTX 3.69  ± 3.51% 
Cingulate  CTX 2.00  ± 2.28% 
Frontal  CTX 3.05  ± 3.21% 
Parietal  CTX 4.20  ± 3.96% 
aPresented as Mean ± Standard Deviation. Regional VT values in units of mL cm-3 were generated using Logan analysis with 




Supplemental Table 5-3. Correlation between age and regional [18F]ASEM Total Distribution Volume corrected for plasma 
free fraction (VT/fP). 
ROI  VT/fPa  Rho (P value)b 
Thalamus  519.36 ± 138.31 0.571 (0.013)* 
Striatum  532.45 ± 147.54 0.674 (0.002)** 
Hippocampus  456.77 ± 111.29 0.573 (0.013)* 
Cerebellar CTX  394.70 ± 96.56 0.587 (0.010)* 
Temporal CTX  509.66 ± 114.43 0.557 (0.016)* 
Occipital CTX  495.68 ± 113.75 0.564 (0.015)* 
Cingulate CTX  502.25 ± 106.32 0.380 (0.120) 
Frontal CTX  493.97 ± 115.60 0.625 (0.006)* 
Parietal CTX  524.68 ± 123.33 0.648 (0.004)** 
aVT/fP was measured in 18 of 25 total healthy individuals and presented as Mean ± Standard Deviation. bSpearman’s rank 
correlation analysis was applied to each test of correlation between age and VT/fP.  Cortex, CTX; Region of Interest, ROI. *P 
< 0.05, which does not account for multiple comparisons in these exploratory analyses. **P <0.0056, which marks 




Supplemental Table 5-4. Lack of correlation between regional [18F]ASEM Total Distribution Volume (VT) and regional 
volume ratio after controlling for age among 25 healthy individuals. 
ROI  Rho (P value)a 
Thalamus  -0. 123 (0.568) 
Striatum  -0.202 (0.344) 
Hippocampus   0.070 (0.746) 
Cerebellar CTX   0.015 (0.946) 
Temporal CTX   0.023 (0.914) 
Occipital CTX   0.431 (0.035)* 
Cingulate CTX   0.296 (0.161) 
Frontal CTX   0.252 (0.236) 
Parietal CTX  -0.046 (0.832) 
aPearson’s correlation analysis was applied to test correlation between regional VT (in units of mL cm-3) and the volume ratio 
(volume relative to intracranial volume, unitless), controlling for age. Cortex, CTX; Region of Interest, ROI. Results from 
each region did not meet the criteria for significance (P <0.0056, which marks significance after applying Bonferroni 




Supplemental Table 5-5. Correlation between age and regional VT estimated using the one-tissue compartmental model 
(1TCM) for [18F]ASEM PET imaging in humans (N=25). 
ROI  Rho (P value)a 
Thalamus  0.534 (0.006) 
Striatum  0.704 (<0.001)* 
Hippocampus  0.630 (0.001)* 
Cerebellar CTX  0.652 (<0.001)* 
Temporal CTX  0.513 (0.009) 
Occipital CTX  0.554 (0.004)* 
Cingulate CTX  0.548 (0.005)* 
Frontal CTX  0.519 (0.008) 
Parietal CTX  0.559 (0.004)* 
Regional VT values in units of mL cm-3 were generated using metabolite-corrected arterial input function and 90 minute 
dynamic data. aSpearman’s rank correlation analysis was applied to each test of correlation between age and regional VT 
generated using 1TCM. Cortex, CTX; Region of Interest, ROI. *P < 0.0056, which marks significance after applying 




Chapter 6: Synthesis and initial in vitro assessment of 
peptide-based agents targeting death receptor 5 
Summary: 
This chapter is focused on the development of peptide-based agents targeting death receptor 5 
(DR5). It details the synthesis of four peptide candidates from peptide design to solid state peptide 
synthesis and then finally to the cyclization of peptide candidates. These peptides were then tested 





A member of the tumor necrosis factor (TNF) receptor superfamily, death receptors (DRs) can 
trigger apoptosis pathways upon binding of TNF-related apoptosis-inducing ligand (TRAIL). Binding 
of TRAIL to the receptors allows them to trigger both intrinsic and extrinsic apoptosis pathways152. 
These death receptors fall in to two categories, death domain containing receptors and decoy 
receptors153. In humans, there are two death domain containing receptors, TRAIL-R1 (DR4) and 
TRAIL-R2 (DR5), that upon binding with TRAIL, form a death inducing signaling cascade and trigger 
apoptosis. The three decoy receptors in humans, TRAIL-R3, TRAIL-R4, and osteoprotegerin (OPG), 
can bind TRAIL but due to a lack of or truncated death domain, they are unable to trigger apoptosis. 
These decoy receptors are seen to inhibit TRAIL-mediated apoptosis by binding TRAIL and lowering 
the concentration of TRAIL available to bind DR4 and DR5154. 
 
TRAIL-based therapies have been highly studied in cancer, due to the attractive potential of TRAIL 
to trigger apoptosis through extrinsic pathways155. This lead to clinical studies using recombinant 
TRAIL which, although showing broad tolerability in humans, failed to show any robust therapeutic 
benefit in humans due to its short half-life and TRAIL-resistance in cancer156,157. To overcome the 
short-half life of TRAIL, our collaborators have developed a PEGylated recombinant human TRAIL 
(TRAILPEG)158–160, that has shown promising therapeutic potential and has a > 16 fold longer half-life 
in monkeys compared to human TRAIL33. Recently, they have discovered a new therapeutic 
potential for TRAIL in non-cancer related diseases, including liver fibrosis, rheumatoid arthritis, and 
scleroderma30,33,161. While these studies show promising results, they lack an effective mechanism to 
monitor disease intervention non-invasively, slowing down the progress of this potentially life-saving 
therapy. 
 
To enable assessment of such therapy, I endeavor to image engagement of death receptor 5 (DR5), 
the receptor through which TRAIL-mediated effects occur5, directly. Imaging of DR5 in vivo will also 
provide a powerful tool to assess not only fibrosis but in a variety of conditions in which the extrinsic 
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apoptotic pathway is involved, including rheumatological conditions162, diabetes163, and 
cardiovascular disease164. Our colleagues have identified a new set of peptides that are specifically 
targeted toward DR5. The coupling of imaging moieties with targeted peptides has proved to be an 
effective strategy that establishes a specific and targeted molecular imaging approach to monitoring 
disease7. I intend to use this approach to functionalize novel DR5-targeted peptide candidates and 
assess the ability of these candidates to bind DR5 in in vitro. 
Methods 
General Procedures 
Solvents of analytical or HPLC grade were purchased from commercial sources and were used as 
received. Fluorenylmethyloxycarbonyl-S-acetamidomethyl-L-cysteine 4-alkoxybenzyl alcohol resin 
(Fmoc-L-Cys(Acm) Wang resin), Fmoc-L-Cys(Acm)-OH, and Fmoc-protected amino acids were 
purchased from Chem Impex Intl. Inc (Wood Dale, IL). Arginine was protected with 2,2,4,6,7-
pentamethyldihydro-benzofuran-5-sulfonyl (Pbf). Asparagine, glutamine, and histidine were 
protected with trityl (Trt). Aspartic acid and glutamic acid were protected with β-tert-butyl (OtBu). 
Lysine and Tryptophan were protected with tert-butyloxycarbonyl (Boc). Serine, threonine, and 
tyrosine were protected with tert-butyl (tBu). Ethyl cyano(hydroxyamino)acetate (Oxyma) was 
purchased from CEM. 6-Carboxyfluorescein (6-FAM) was purchased from Astatech. All other 
reagents were purchased from Sigma Aldrich. Low-resolution electrospray ionization-mass 
spectrometry (ESI-MS) data were obtained using an Agilent Technologies 1260 series LCMS Single 
Quad System connected to a variable wavelength detector. 
Solid State Peptide Synthesis of Acm-protected peptides 
Linear peptide synthesis was carried out on a CEM Liberty Blue Automated peptide synthesizer 
using a traditional Fmoc protection strategy at a reaction scale of 0.1 mmol. Fmoc protecting groups 
were removed using 20% piperidine in dimethylformamide (DMF), followed by activation of carboxyl 
groups and amino acid coupling. Fmoc-L-Cys(Acm)-resin was used for all syntheses. Once 
synthesis was complete, the peptide-resin was removed from the synthesizer and transferred to a 
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filtered reaction vessel. Resin cleavage and global deprotection of protecting groups was done 
concurrently, based on a protocol by Pedersen et al.165 The peptide-resin was washed three times 
with DMF, followed by three washes with dichloromethane (DCM), and dried under high vacuum for 
1-4 hours. Resin cleavage and global deprotection of protecting groups was achieved using a 
cleavage cocktail of trifluoroacetic acid (TFA)/water (H2O)/triisopropalsilane (18/1/1). The peptide-
resin was suspended in 5 mL of cleavage cocktail and rocked for 2 hours at room temperature (RT). 
Following cleavage, the peptide was filtered from the resin, the resin was washed with TFA, and the 
peptide was precipitated with cold diethyl ether. The precipitate was centrifuged for 5 minutes at 
4000 revolutions per minute (RPM), producing a peptide pellet and a diethyl ether supernatant. The 
ether was decanted, the peptide was washed twice more with diethyl ether, and the peptide pellet 
was dried with forced air before being prepared for lyophilization or high performance liquid 
chromatography purification. 
High Performance Liquid Chromatography (HPLC) purification of Acm-protected 
peptides 
Reverse phase high performance liquid chromatography was performed on an Agilent Technologies 
1260 Infinity semi-preparative HPLC system (Wilmington, DE) equipped with a Phenomenex, C18 
Luna, 10u, 10 x 250 mm2 column at a 10 mL/min flow rate. Peptides were eluted using a gradient of 
H2O containing 0.1% TFA and acetonitrile containing 0.1 % TFA. Peptides were detected at 215, 
255, and 450 nm wavelengths. The following gradients were used for each candidate peptide: 
DP1-ACM-FAM: 10%-60% Acetonitrile + 0.1% TFA: H2O + 0.1% TFA in 30 minutes. DP1-ACM-FAM 
was eluted at 11.92 minutes. 
DP2-ACM-FAM: 15%-30% Acetonitrile + 0.1% TFA: H2O + 0.1% TFA in 30 minutes. DP2-ACM-FAM 
was eluted at 4.73 minutes.  
DP3-ACM-FAM: 10%-60% Acetonitrile + 0.1% TFA: H2O + 0.1% TFA in 30 minutes. DP3-ACM-FAM 
was eluted at 9.13 minutes. 
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DP4-ACM-FAM: 15%-75% Acetonitrile + 0.1% TFA: H2O + 0.1% TFA in 30 minutes. DP3-ACM-FAM 
was eluted at 6.06 minutes. 
Peak-based fraction collection was completed using the automatic fraction collector integrated into 
the Agilent system by setting a peak absorbance threshold. Collected fractions were combined, 
concentrated on the rotary evaporator, and lyophilized. Lyophilized products were stored at -20 °C 
until ESI-MS characterization.  
Cyclization of Acm-protected peptides 
Cyclization of Acm-protected peptides was adapted from the protocols of Andreu et al.166 and Zhang 
et al.167 The Acm-protected peptide was dissolved in 4:1 glacial acetic acid: H2O to reach a final 
concentration of 100 µmol/100 mL. The solution was stirred at 25 °C and protected from light. To 
start the reaction, 5 equivalents of iodine (I2) per Acm protecting group was added to the solution, 
resulting in a dark orange solution. The reaction was monitored via HPLC and was stopped once the 
starting material peak was no longer present. To stop the reaction, ice-cold diethyl ether (9 volume 
equivalents) was added to the reaction solution to simultaneously quench the I2 and isolate the 
peptide product. The solution was cooled on dry ice for 3 minutes followed by centrifugation for 3 
minutes at 5000 RPM. The ether solution was decanted, and the cyclic peptide product was 
prepared for HPLC purification. Reverse phase HPLC was performed as described above with the 
following gradients used for each candidate peptide: 
DP1c-FAM: 10%-60% Acetonitrile + 0.1% TFA: H2O + 0.1% TFA in 30 minutes. DP1c-FAM was 
eluted at 12.6 and 12.9 minutes. 
DP2c-FAM: 15%-50% Acetonitrile + 0.1% TFA: H2O + 0.1% TFA in 30 minutes. DP2c-FAM was 
eluted at 7.7 and 8.0 minutes. 
DP3c-FAM: 10%-60% Acetonitrile + 0.1% TFA: H2O + 0.1% TFA in 30 minutes. DP3c-FAM was 
eluted at 9.6 minutes. 
DP4c-FAM: 15%-70% Acetonitrile + 0.1% TFA: H2O + 0.1% TFA in 30 minutes. DP4c-FAM was 




Human colorectal carcinoma cells (HCT116) were obtained from Dr. Seulki Lee. HCT116 
constitutively express DR5168. The HCT116 cells were maintained in RPMI 1640 medium (Corning 
Cellgro), supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (Corning 
Cellgro). Cell cultures were maintained at 37 °C and 5% carbon dioxide (CO2) in a humidified 
incubator. 
In vitro binding of FAM-labelled peptides 
To assess the binding of our candidate peptides to death receptor 5, we performed flow cytometry 
analysis. Cells were detached using nonenzymatic cell dissociation buffer (Gibco) and suspended in 
phosphate-buffered saline (PBS) buffer supplemented with 2 mM of EDTA and 1% FBS (FACS 
buffer) to a final concentration of 1 x 106 cells/100 µL solution. 100 µL of the FAM-labelled peptide 
was added to the aliquots (final concentration: 200 nM), mixed, and left to incubate for 1 hour at 37 
°C and 5% CO2 in the dark. Cells were then washed three times with FACS buffer, resuspended in 
FACS buffer, and filtered before flow cytometry analysis. Flow cytometry analysis was completed on 
a FACSCalibur flow cytometer (Becton Dickinson), with at least 20,000 events recorded. 
Results 
Synthesis and purification of Acm-protected peptides 
Peptide synthesis of Acm-protected peptides was completed without issue on the Liberty Blue 
automated peptide synthesizer. For each candidate peptide, 6-FAM was added at the N-terminal of 
the peptide as the last step of the synthesis. Washing, drying, and global deprotection of the 
peptides from their resins resulted in peptide products that were separable via HPLC. A 
representative HPLC trace of DP1-ACM-FAM is shown in Figure 6-1. ESI-MS characterization of 
peptide candidates confirmed the major product peaks collected corresponded to the Acm-protected 











Figure 6-2. ESI-MS analysis of DP1-ACM-FAM. 
A. LC chromatogram of purified DP1-ACM-FAM detected at wavelength 220 nm. 






Cyclization of Acm-protected peptides 
To form cyclic peptides via disulfide bond formation, Acm-protected peptides underwent I2 oxidation 
to simultaneously remove the Acm-protecting groups and form the disulfide bonds. Within 60 
minutes, formation of product peaks was observed for all peptide candidates (Figure 6-3). Reaction 
time for each peptide candidate differed slightly, with DP1c-FAM taking 180 minutes to reach 
completion and DP3c-FAM taking closer to 300 minutes to complete. At later timepoints, the 
additional product peak formation was observed, most likely due to side chain reactions. 
 
ESI-MS characterization of cyclic peptide candidates resulted in the identification of the fully 
deprotected cyclic product of interest. Interestingly, for peptide candidates DP1c-FAM and DP2c-
FAM, the two major product peaks of interest corresponded to the major product of interest, likely 
due to the presence of isomers169. 
Flow cytometry 
Initial flow cytometry assessment of the peptide candidates binding to HCT116 colorectal cancer 
cells is shown in Figure 6-4. All peptide candidates tested demonstrated binding to the HCT116 





Figure 6-3. HPLC analysis of cyclic reaction of DP1c-FAM at 60 minutes. 
Detection at 220 nm is shown. The starting material is shown at 12.0 min and the major product peaks of DP1c-FAM are 





Figure 6-4. Flow cytometry analysis of DP1c-FAM, DP3c-FAM, and DP4c-FAM in HCT116 cells. 
The pink peak corresponds to the cells only peak (control) and the blue/green peaks correspond to the HCT116 cells treated 
with the cyclic peptides. 
  




We have shown a solid approach to the synthesis of cyclic peptides identified via phage display. 
These peptides were synthesized on the solid support, functionalized with a fluorescent label, and 
converted into cyclic molecules through the formation of a disulfide bind. When testing the ability of 
these peptides to engage DR5 in vitro, we saw that these peptides were able to engage DR5 
expressed on human colorectal cancer HCT116 cells. 
 
When approaching the synthesis of these candidate peptides, it was important to control for the 
labeling of the peptides at the N-terminus. This is because we do not know which amino acids 
contribute to the binding of the peptide to DR5, so labeling of the peptide at the N-terminus was 
done to minimize the alteration of the bioactivity of these peptide candidates170. Since all the 
candidate peptides contained lysine residues, it was essential that the labeling of the peptide with 6-
FAM was done prior to deprotection of the peptide candidates. This is because unprotected lysine 
contains an ε-amino group that can also readily be labeled with 6-FAM171. To avoid this, we moved 
forward with labeling of the peptide on the solid support followed by subsequent deprotection and 
cyclization of the peptides. 
 
Since engineered peptides suffer from low stability in vivo, we moved forward with a cyclic strategy 
when preparing our candidate peptides. Cyclic peptides are known to have longer half-lives in vivo 
due to increased structural stability and resistance to proteolysis172 as well as improved binding 
ability due to conformational rigidity resulting in more entropically favored interaction173. Additionally, 
since our candidate peptides contain free sulfhydryl groups in their unprotected, linear form, there 
was the potential for random multimerization of these peptides. To avoid this issue and improve the 
stability of these peptides, we moved forward with cyclizing these peptides by leveraging their 
cysteine groups to form disulfide bonds. Although there are numerous approaches to disulfide bond 
formation in peptides174, we chose to use an I2 oxidation approach that simultaneously removed the 
Acm protecting groups and formed the disulfide bonds due to its simplicity and favorable reaction 
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outcomes175. Since the Acm protecting group is stable under most standard peptide synthesis 
conditions and not TFA-labile176, this allowed the peptides to remain Acm-protected after global 
deprotection of other the protecting groups and resin cleavage, preventing unwanted side reactions 
and allowing us to control the formation of the cyclic product. Interestingly, the cyclization of DP1c-
FAM and DP2c-FAM resulted in the production of two product peaks that had the same molecular 
weight as our cyclic product of interest. Although these results were unexpected, it is most likely due 
to the formation of isomers during the formation of the disulfide bond linkage169. 
 
When the peptides were tested in the HCT116 cells, we observed modest binding of the peptide 
candidates via flow cytometry, with DP3c-FAM showing the most binding to the HCT116 cell line. 
While these studies show favorable binding of the peptides to DR5, more work is necessary to fully 
characterize the binding ability of these peptide agents. 
Future Work 
To fully characterize these peptide candidates, future work will be focused on further 
characterization of the ability of these agents to bind DR5. To assess the bioactivity of these peptide 
candidates, we plan to leverage affinity-based approaches, such as bio-layer interferometry (BLI) or 
surface plasmon resonance (SPR), to provide valuable information of the binding of these agents as 
well as affinity characteristics, including dissociation constant (KD) values, which will be used to 
determine the optimal DR5 peptides. 
 
Once an optimal candidate peptide has been identified, the peptide candidate will be prepared for 
both NIRF and PET/SPECT applications by leveraging the N-terminal alpha-amino group as the site 
of modification for both targets. The peptides will be conjugated with a NIR dye, IRDye 800CW® (LI-
COR Biosciences), or 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) enabling 
the peptides to be used for NIRF or SPECT/PET applications, respectively. DOTA-peptides will 
undergo subsequent radiolabeling with 111In or 64Cu to be functionalized for SPECT or PET. Probes 
will be purified using HPLC and characterized using mass spectrometry. In addition to previous in 
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vitro experiments, specific binding will be further assessed using cellular uptake and fluorescence-
activated cell sorting (FACS) studies using human tumor cell lines, such as DR5+ colon (HCT-116), 
breast (MCF7), and prostate (PC3). Once these peptides have been fully characterized and tested in 
in vitro models, we will utilize these functionalized peptides to monitor TRAIL-mediated events in 
vivo in mouse xenograft models. 
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Teaching Assistant, Department of Biomedical Engineering, JHU 
Supervising Instructors: Dr. John Hickey, Elana Ben-Akiva 
Spring 2020 
  
Systems Bioengineering Lab I (EN.580.421) 
Teaching Assistant, Department of Biomedical Engineering, JHU 
Supervising Instructor: Dr. Benjamin Bejar-Haro 
Fall 2018 
  
Introduction to Scientific Computing in BME (EN.580.200) 
Teaching Assistant, Department of Biomedical Engineering, JHU 
Supervising Instructor: Dr. Winston Timp 
Fall 2017 
  
General Chemistry I (CHEM 102) 
Merit Instructor, Department of Chemistry, UIUC 
Supervising Instructor: Dr. Gretchen Adams 
Spring 2015 
  
Biomedical Instrumentation (BIOE 414) Spring 2015 
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Student Grader, Department of Bioengineering, UIUC 
Supervising Instructor: Dr. Wawrzyniec Dobrucki 
  
Signals and Systems in Bioengineering (BIOE 205) 
Student Grader, Department of Bioengineering, UIUC 
Supervising Instructor: Dr. Marcia Pool 
Spring 2014 
  
Conservation Principles of Bioengineering (BIOE 201) 
Student Grader, Department of Bioengineering, UIUC 
Supervising Instructor: Dr. Princess Imoukhuede 
Fall 2013 
  
Engineering Grand Challenges (ENG 198) 
Engineering Learning Assistant, College of Engineering, UIUC 
Supervising Instructor: Dr. SungWoo Nam 
Fall 2013 
 
Engineering Orientation (ENG 100) 
Engineering Learning Assistant, College of Engineering, UIUC 
Supervising Instructor: Michelle Adeoye 
Fall 2013 
  
HONORS AND AWARDS 
Bradley-Alavi Student Fellowship, Society of Nuclear Medicine and Molecular 
Imaging 
2019 
Featured Article of the Month, Journal of Nuclear Medicine 2018 
NSF GRFP, Honorable Mention 2016 
Finalist, Cozad New Venture Competition 2015 
Distinguished Service Certificate, Alpha Phi Omega 2015 
Kinetic Leadership Knot, Alpha Phi Omega 2014 
Second Place, Saint Louis University Elevator Pitch Competition 2014 
First Place Venture Capitalist Pitch, Coulter College 2014 
Tau Beta Pi Honors Fraternity 2013 
James Scholar, College of Engineering, UIUC 2011 – 2015 





Member, BME PhD Equity, Diversity, and Inclusion (EDI) Committee, 
JHU 
2020 - Present 
 Served as a member of the founding EDI committee and helped develop the group’s 
initiative and goals 
 Leads the initiative on mental health advocacy and education for graduate students 
 
Volunteer, Thread Inc., Baltimore, MD 2016 - Present 
 Mentored, tutored, and supported high school student to ensure graduation 
 Regularly tutored multiple students during after school sessions 
 
President, BME Graduate Student Council, JHU 2016-2017 
 Ran monthly council meetings, oversaw all council members and council initiatives, and 
led the planning for the Annual BME Retreat. 
 




 Acted as representative for the BME Ph.D. students to the Graduate Student Association 
by regularly attending meetings, voting on behalf of BME Ph.D. students, and 
communicating updates to the BME Ph.D. council. 
 
Alpha Phi Omega, Alpha Alpha Chapter, UIUC 2012-Present 
 Independent Projects Chair (Fall 2013) 
o Verified and documented 1000+ service hours completed by our chapter’s active 
members 
 Active Member (Fall 2012 – Spring 2015) 
o Completed 200+ service hours over my 6 semesters of active membership 
o Completed three intensive leadership courses through the APO LEADS 
leadership development program  
 External Service Committee Director (Spring 2014) 
o Managed and helped lead a 10 person committee focused on planning service 
events with community partners 
 Advisor Relations Chair (Fall 2014) 
o Served as the official liaison between the executive board and advisory board 
 National Service Week Chair (Fall 2014) 
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o Coordinated, promoted, and executed a week of service projects to celebrate 
National Service Week 
 Vice President of Service Internal (Spring 2015) 
o Served as a member of the Executive Board and voted on important chapter 
decisions 
o Led a committee focused on creating new service events and forming new 
service partnerships for the chapter 
 Alumni (2015-Present) 
 
Biomedical Engineering Society, UIUC Chapter 2012-2015 
 Treasurer (2013-2015) 
o Maintained a detailed record of the chapter’s financial transactions and collected 
all membership dues 
 President (2014-2015) 
o Supervised all society affairs and activities, presided over all meetings, and 
oversaw all chapter officers and committees. 
o Led an initiative to increase chapter membership, increasing membership by 
almost 50% during my tenure. 
 
Bioengineering Undergraduate Advisory Board, UIUC 2012-2015 
 Sophomore Representative (2012-2013) 
o Acted as representative to the Advisory Board for the sophomore Bioengineering 
class 
 Junior Representative (2013-2014) 
o Acted as representative to the Advisory Board for the junior Bioengineering class 
 Committee Chair (2014-2015) 
o Oversaw the Advisory Board and acted as the main contact between the 
Bioengineering students and the department 
o Organized and facilitated monthly meetings focused on providing feedback on 
curriculum and program changes 
 
Student Volunteer, Presence Health, Champaign, IL Spring 2012- Fall 2013 
 Stocked nurses’ stations, prepared patient admission packets, and responded to patient 
request on the Medical-Surgical/Oncology floor. 
 Completed 100+ service hours over the four semesters volunteering. 
 
